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”what constitutes happiness is a matter of dispute... 
some say one thing and some another, 
indeed, very often, the same man says different things at different times: 
when he falls sick he thinks health is happiness, when he is poor, wealth” 
 
Aristotle 384-322 BC 
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ABSTRACT 
This thesis investigates the health-related quality of life (HRQL) among 
surgically treated oesophageal cancer patients. 
 
The established curative treatment for oesophageal cancer is extensive surgery 
with a high risk of morbidity and a limited chance of long term survival. Only 
every third patient is suitable for surgery. Subjective outcomes such as HRQL are 
therefore of particular importance among this group of patients.  
In three of the four studies (I, II, IV) included in this thesis, a nationwide Swedish 
cohort of oesophageal cancer patients, operated in 2001-2005, was used, while in 
study III a British cohort of operated patients was used. In all studies, HRQL was 
assessed with an international validated core questionnaire on the symptoms and 
functions of cancer (EORTC QLQ-C30). Studies I, II and IV also included an 
oesophageal cancer specific module (EORTC QLQ-OES18). In Studies I and III a 
difference in transformed mean scores of at least 10 points on a scale of 0-100 
was used as a cut-off for clinical relevance. In Studies II and IV raw scores were 
categorised into good or poor HRQL.  
In Study I, the long term HRQL after oesophageal cancer surgery was 
investigated. HRQL was shown to be similar both six months and three years 
postoperatively, which suggests that the long-standing HRQL level is already 
established at six months. The HRQL was poorer than that of the general 
population. 
Study II assessed if patient and tumour characteristics affect HRQL six months 
postoperatively. Sex, age and BMI showed no associations while co-morbidity 
and tumour characteristics such as histology and tumour stage affected HRQL. 
The findings may be useful for clinical decision making. 
Study III explored if both baseline HRQL and changes in HRQL from baseline to 
six months’ follow-up was associated with survival. Dyspnoea at baseline was 
associated with an increased risk of mortality. Not recovering physical function 
and worsening of pain and fatigue were linked with a higher risk of mortality. 
Therefore, changes in HRQL might be prognostic and of importance when 
planning follow-up and supportive care. 
Study IV analysed whether postoperative HRQL was associated with survival. 
Poor HRQL measures were associated with increased risk of mortality. This 
knowledge could be used for prognostic discussions and intensity of the clinical 
follow-up. 
In conclusion, this thesis shows that measures of HRQL could aid decision-
making prior to treatment and in planning the follow-up of oesophageal cancer 
patients. 
 
Keywords: Oesophageal cancer, Surgery, Health-related quality of life, HRQL, 
Survival 
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LIST OF ABBREVIATIONS AND 
MEDICAL TERMS 
Abbreviation/ 
Medical Term 
Explanation 
AC Adenocarcinoma 
Anorexia (cancer) Loss of desire to eat, prompted by the growing tumour1. 
ANS Autonomic nerve system. A part of the peripheral nerve 
system working without consciousness and regulating most 
organs. Divided in the parasympathetic part which controls 
salivation, lacrimation, urination, digestion and defecation 
while the sympathetic part controls actions requiring quick 
responses such as “fight or flight reaction”  
Anterior The front surface of the body, placed in front. 
BMI Body Mass Index. Weight(kg) /(length(m) *length(m)) 
Bronchoscopy Visualizing of airways via an instrument inserted from the 
mouth or nose.  
Cachexia (cancer) Multi factorial syndrome with disturbed immune system, loss 
of muscle mass and fat causing fatigue and possible loss of 
weight2,3.  
Caudal Near the tail/hind parts of the body, or inferior. 
Cervical Near the neck. 
CT Computed tomography, medical 3D imaging via radiology. 
En bloc, en bloq Removing everything from the vertebral column to the 
pericard in one piece to minimize tumour during oesophageal 
cancer surgery. 
Eradicating Taking out all lymph nodes in the areas  
Gastrocopy Visualising of the oesophagus, stomach and duodenum via an 
instrument inserted via the mouth. 
Gastroplasty Plastic surgery to the stomach. 
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Hepatomegaly Enlarged liver. 
HRQL Health-related quality of life. 
Laparascopy Operation in the abdomen through a small incision with aid 
from a camera. 
Laparatomy Operation in the abdomen. 
LES Lower Esophageal sphincter. 
Lymphadenopathy Disease of the lymph nodes or swollen/enlarged nodes. 
Mediastinum The middle section of the chest cavity with all organs except 
for the lungs. 
N/A Not available. 
Parasympatic nerve See ANS. 
PET Positron emission tomography, a nuclear medical 3D 
imaging. A biological active molecule is added to the patient 
and detected by gamma rays. 
RCT Randomized Controlled Trial. 
Referred pain Pain perceived at a site remote from the origin of an injury, 
such as pain in the left arm during a heart attack. 
SCC Squamous cell carcinoma 
SECC-registry Swedish Esophageal and Cardia Cancer registry, a nationwide 
cohort collected between 2001 and 2005. 
Sympathetic nerve  See ANS. 
Thoracoscopy Visualisation of lungs and chest cavity via a camera inserted 
through the chest wall. 
TNM Classification of malignant tumours, se page 19.  
Tumour (lymph) Nodes Metastasis. 
Upper gastrointestinal 
database 
A hospital-based cohort started in 2000 in Bristol, U.K. 
Virchovs node The signal node, an enlarged hard node just above the left 
clavicle suspected of containing metastases from abdominal 
malignancy. 
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INTRODUCTION 
 
The Context and Theoretical Framework 
This book is a scientific thesis in medicine. The book includes the background to 
the four studies undertaken, an account of the four studies and a concluding 
discussion of methodological issues. The theoretical framework mainly conforms 
with earlier relevant scientific articles published in international medical journals. 
All of these articles have strengths and weaknesses, but since the aim has been to 
produce a comprehensive text, those characteristics have not been given space.  
 
Oesophageal Cancer  
The word oesophagus derives from the Greek oisein (to carry) and phagos (to eat) 
and is the Latin name for the foodline. Oesophageal cancer is aggressive and the 
cure is through extensive surgery with typically long recovery time. Oesophageal 
cancer is a physically and emotionally devastating disease affecting the general 
wellbeing and quality of life and fundamental aspects of life e.g. eating, drinking 
and socializing4-6. 
 
Health-Related Quality of Life  
Health-related quality of life (HRQL) is a concept assessing symptoms and 
functions related to a disease or its treatment from the patient’s perspective. It is 
hypothesized that HRQL’s multidimensional subjective approach provides early 
indications of how the patient as a host responds to for example a cancer and how 
well he is recovering after treatment7. 
 
Rationale for the Thesis 
Little is known about long term HRQL following oesophageal cancer surgery. It is 
for example uncertain whether the postoperative symptoms or problems are 
transient or persistent even if the patients’ survival is similar to that of the general 
population8. It is unknown to what extent clinical features such as patient or tumour 
characteristics influence the HRQL and little is known whether a change in patient-
reported deterioration or postoperative differences between patients are actually 
associated with survival. In a disease with such poor prognosis all warning signs 
can be of great importance.   
 
Finally, this thesis focuses on patients with curative-intending treatment who, we 
need to bear in mind, constitute the minority of oesophageal cancer patients. 
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BACKGROUND  
 
THE OESOPHAGUS 
Gross Anatomy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The oesophagus and its anatomic relations.                                                       
Netter Illustration from www.netterimages.com, © Elsevier Inc. All rights reserved. 
The oesophagus is an 18 to 26 cm long muscular tube running from the pharynx 
to the stomach9. It commences around 18 cm from the incisor teeth at the level of 
the inferior part of cricoid cartilage, just beneath the laryngeal prominence known 
as the Adam´s apple. Descending between the trachea and spine it passes behind 
the tracheal bifurcation and the aortic arch. Further down it passes anterior of the 
aorta and close to the left atrium of the heart, to enter the diaphragmatic hiatus 
before ending at the oesophagogastric junction. It is well protected in the thoracic 
cage. The location could delay the detection of a tumour until it has already 
spread, and necessitate complicated operations since it is close to vital organs. 
  18 
Histology 
In the cross-section, the oesophagus consists of four layers. Outermost the fibrous 
adventitia, followed by the muscular layer - with an external longitudinal layer, 
and an internal circular layer. The upper part of the inner layer comprises 
voluntarily controlled striated muscle fibres, while the lower third consists of 
involuntarily controlled smooth muscle fibres. At the caudal end there is a 
thickening and interconnection of muscle fibres, forming the lower oesophageal 
sphincter (LES). Within the muscular layer is the loose connective tissue layer – 
the submucosa and innermost the muscosa with thin smooth muscles and squamous 
epithelium. The oesophagus lacks serosa which allows tumours to spread easier and 
challenges repair of luminal disruptions9.  
 
Innervations 
The autonomic nerve system’s sympathetic fibres mediate discomfort and pain, 
regulate vessel construction and peristaltic activity. The parasympathetic nervus 
vagus mediates mechanical, chemo and thermo stimuli, regulates glandular 
secretion and motor innervations for distal smooth muscles and the LES. The vagal 
nerves give rise to the recurrent laryngeal nerve on both sides. Both these nerves 
linger around the oesophagus and might be injured during surgery, especially on 
the left side, where it hooks around the aortic arch. Such injury might result in 
hoarseness, difficulties in swallowing and aspiration with respiratory problems9. 
 
Lymphatic Drainage 
Lymph is drained in a network of channels in the oesophageal submucosa. Lymph 
from the proximal third is drained via deep cervical nodes to the thoracic duct, 
while lymph from the middle third drains into superior and inferior mediastinal 
nodes, and the lower third drains via gastric and celiac nodes to the cisterna chyli9. 
The cisterna chyli is connected to the thoracic duct, which allows metastases to 
spread in all directions. The flow is unpredictable, meaning that no particular 
lymph node is typically affected first, as in the case of breast cancer and the 
sentinel node10,11.  
 
Physiology 
While processed food is voluntary moved backwards, it triggers the closure of the 
airway and enters the oesophagus under involuntary control. While peristaltic 
waves propel the food downwards the normally collapsed oesophagus distends up 
to a couple of centimetres9. This yielding capacity allows the tumour to grow 
almost unnoticed. After the food has entered the stomach, the LES, in conjunction 
with a sphincter in the upper oesophagus and the diaphragm, prevents the 
backflow of food and gastric acid (reflux)9.  
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OESOPHAGEAL CANCER 
 
Histological Types 
Oesophageal cancer has several different origins although two types serve for up to 
90% of all cases, i.e. squamous cell carcinomas (SCC) and adenocarcinomas 
(AC)12. More rare types include other carcinomas, melanomas, carcinoids, and 
lymphomas13. SCC are often found in the middle, or perhaps more commonly in 
lower part, while three quarters of the AC originate in the lower part of the 
oesophagus12-14. Only a minority of the patients have tumours in the upper 
oesophagus12-14. 
 
Occurrence  
Oesophageal cancer is the sixth most common cancer-related cause of death 
worldwide15. SCC is particularly common in southern and eastern Africa, Japan 
and in a geographic belt from northern Iran to north central China, where the 
highest incidence in the world (27 cases per 100,000 males) can be found15. There 
is a stable or decreasing number of SCC in most populations16,17. In contrast, AC is 
striking Western nations such as North America and Western Europe with an 
increasing incidence9,16-18. The sex ratio differs from 7:1 in eastern Europe to close 
to unity in high risk areas 15. The sex variation for SCC can be explained by 
different exposure to the main risk factors, although no explanation for the sex 
pattern in AC has yet been found17,19-21. The highest rate of AC, reported among 
white males, is for reasons yet unknown, in the United Kingdom (U.K.)18. Both 
histological types have an unexplained marked variation between different ethnic 
groups within the same geographic region9. In Sweden there are approximately 400 
new cases of oesophageal cancer reported annually, which corresponds to 
approximately 1% of all tumours annually reported to The National Board of 
Health and Welfare22.  
 
Risk Factors 
Established risk factors for AC are; reflux, Barretts esophagus (an abnormal 
change in cells of the lower oesophagus, due to chronic reflux) and high body 
mass index (BMI)13,19,23,24, while the main risk factors for SCC are tobacco 
smoking and alcohol intake, especially in combination13,25. Furthermore, SCC has 
also been associated with low intake of fruit and vegetables24 and low 
socioeconomic status13,25. Several risk factors have been debated e.g. 
environmental carcinogens, malnutrition in central Asia, China and southern 
Africa, hot tea in Iran as well as hot mate in south America, heredity among 
families with tylosis and genetic predisposition in Japan and among US 
Japanese13,15. Infection with Helicobacter pylori has been found to be protective, 
probably due to reduced acidity from gastric atrophy and the production of 
ammonia26.   
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Symptoms 
Early symptoms are rare although symptoms arise from local obstruction, local 
invasion and metastasis. The first symptom in the large majority of the patients is 
difficulties in swallowing solid or fluid foods (dysphagia), which is experienced 
due to oesophageal obstruction12,13,27,28. At that time, patients have often gradually 
changed their dietary habits and more than half of the patients have experienced 
weight loss likely due to dysphagia, anorexia or cancer-cachexia12,29. The 
obstruction can further result in reflux or vomiting12. Symptoms from the local 
invasion might be pain (from the oesophagus or referred to the back and the right 
upper abdominal corner)28 or hoarseness and coughing due to laryngeal nerve 
overgrowth12. In addition to these oesophageal cancer-specific symptoms, general 
cancer symptoms such as fatigue could be present. 
 
Diagnosis 
Physical examination might reveal a patient who has lost weight, but usually 
shows no other signs13. In the presence of metastatic disease, lymphadenopaty 
might be found, especially in the left supraclavicular fossa (Virchovs node) or 
hepatomegaly13. When a tumour is suspected, a patient usually performs both a 
gastroscopy with biopsies and a computed tomography (CT) with intravenous 
contrast medium of the chest, abdomen and pelvis for evaluation of the extent of 
the tumour, involved lymph nodes and distant metastasis12,13. Furthermore, an 
endoscopic ultrasound (EUS) with simultaneous fine needle aspiration could be 
performed for local and regional tumour staging13. Suspicion of local invasions in 
the airways prompts a broncoscopy30. Finally, a positron emission tomography 
(PET) has high sensitivity for detecting distant metastases, which can be 
confirmed or excluded with a precise location via a CT30. In some cases a 
thoracoscopic or a laparoscopic staging can be performed, but since they are 
invasive they are more rarely used. 
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Classification/Staging the Tumour 
Staging is of great importance to the determination of treatment strategy, and it is 
usually set via a the tumour-node-metastasis (TNM) classification system31. The 
TNM stage is basic data for grouping to tumour stage 0-IV as shown in Table 1 
and 2. 
Table 1. Staging with TNM for oesophageal cancer according the 5th version of TNM 
Classification of malignant tumours. 
Primary tumours depth of wall invasion (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of tumour 
Tis Carcinoma in situ 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades nearby structures 
Occurrence of regional lymph nodes (N) 
NX Regional nodes cannot be assessed 
N0 No regional node metastases 
N1 Regional node metastases 
Occurrence of distant metastases (M) 
MX Distant metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
M1a- in celiac lymph nodes (lower tumours)  
or cervical nodes (upper tumours) 
M1b- other distant metastases 
Sobin L.H., Wittekind Ch, TNM Classification of Malignat Tumours. 5th ed. New Jersey: 
Reprinted with the kind permission of John Wiley & Sons Inc. 
 
Prognosis 
Patients are often diagnosed at an advanced stage, and more than 50% of the 
patients have metastatic disease or an unresectable tumour when diagnosed12,13. 
Curatively-intended treatment is only offered to those with local advanced disease 
without metastatic spread. The overall 5-year survival rate is as low as 10% in 
Europe15, while the unselected postoperative 5-year survival is about 31%32. 
Survival is closely connected to the tumour stage, where stage 0 has a 95% 5-year 
survival after curative surgery, stage I: 50-80%, stage II: 10-40% and stage III: 
10-15%13. Patients with stage IV under palliative therapy have a median survival 
outlook of less than one year13. The majority of the patients undergoing surgery 
have stage III at the time of diagnosis12,13. Recurrences are likely to come within 
the first postoperative year11, so patients who survive for three years have the 
same prognosis as the general population8. 
Table 2.                                            
Grouping from TNM to stage 0-IV 
Stage 0 TisN0M0 
Stage I T1N0M0 
Stage IIA T2N0M0, T3N0M0 
Stage IIB T1N1M0, T2N1M0 
Stage III T3N1M0, T4 any N or M0 
Stage IV Any T, any N, M0 
Stage IVA Any T, any N, M1a 
Stage IVB Any T, any N, M1b 
  22 
Curative Treatment 
There are three main curative treatment options; radiotherapy, chemotherapy and 
surgery, which can be combined13. Several randomized controlled trials (RCTs) 
have evaluated survival, tumour response and complications as primary endpoints 
but often lacked in statistical power to detect any differences in outcome between 
treatment groups33. However, a continuous re-evaluation of management strategies 
is important12. So far, surgery is the standard single treatment, and the established 
curative treatment for fit patients is radical surgery13,34,35. Swedish patients are only 
offered surgery as a curative treatment. 
 
Therapy without Surgery 
Radiotherapy alone, given to non-fit patients, has shown conflicting results 
compared to surgery alone36-38. Combined radiotherapy and chemotherapy has 
shown a similar survival rate to neoadjuvant chemoradiotherapy followed by 
surgery39,40, but prolonged median survival compared to radiotherapy alone41,42. In 
the U.K., combined chemo and radiotherapy is offered as a curative to patients not 
fit for surgery with a locally advanced cancer (AC or SCC: T2N1M0, T3N0/1M0 
and SCC: T3/4N0/1M0).  
 
Neoadjuvant Treatment 
Neoadjuvant treatment means any oncological treatment, such as radiotherapy or 
chemotherapy, prior to surgery. The use of neoadjuvant therapy differs between 
countries, for example patients in the U.K. with locally advanced cancers (AC/SCC 
in stages T2N1M0, T3N0/1M0) are offered neoadjuvant therapy, while it is less 
common in Sweden. A recent meta-analysis of twelve studies including 2097 
patients concluded that preoperative chemotherapy might be beneficial for survival 
compared to surgery alone, but further studies are needed, since a risk of increased 
toxicity and preoperative mortality was found34. Neoadjuvant radiotherapy did not 
improve the survival rate, compared to surgery alone, in a meta-analysis of data 
from 1147 patients43. Combined neoadjuvant chemotherapy and radiotherapy could 
be beneficial in several ways; chemotherapy reaches micro-metastases outside the 
radiation field and enhances radiosensitivity, while radiation suppresses 
locoregional recurrences. Out of eight RCTs investigating benefits with combined 
neoadjuvant radiotherapy and chemotherapy, two had sufficient power and neither 
reported any benefit13,44. 
 
Preoperative Care 
The extensive surgery demands a fit patient who is preferably examined by a 
multidisciplinary team of surgeons, oncologists, radiologist, anaesthetics, nurses, 
physiotherapist and dieticians. Further, tests for cardiac- and pulmonary function 
are performed.  
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The Operation  
According to Swedish data only one quarter of the patients with oesophageal 
cancer are operated; the majority of the patients are probably excluded, since they 
are not fit for surgery and/or have an unresectable tumour32. The operation offers a 
chance of cure, but involves a high morbidity and mortality risk. There are two 
main possible approaches; transthoracic or transhiatal. The transthoracic approach 
is commonly used in Sweden. 
 
The transthoracic approach usually combines a laparatomy (upper abdominal 
incision) for dissection of the stomach and lower oesophagus, including extensive 
dissection of nodal tissue along the celiac trunk with branches45 with a right sided 
posterolateral thoracotomy at the fifth intercostal space for further dissection of the 
upper oesophagus (Ivor Lewis).  
The right side is used for middle or proximally located tumours, while some 
surgeons prefer to approach lower tumours from the left45. During the thoracic part, 
one lung will be deflated for easier dissection of the mediastinum. The method 
facilitates a good overview and easier en bloc techniques. 9  
 
The transhiatal approach aims to minimize surgical damage by way of blunt 
dissection of the oesophagus up to the lower pulmonary veins from an upper 
abdominal incision, thereafter a neck incision is made to strip the upper 
oesophagus. 9Although not yet proven, it has been claimed that fewer respiratory 
complications, lower risk of mediastinitis, and a shorter operation time are among 
the advantages9.  
 
In both techniques the stomach, or sometimes the jejunum or colon, serves as 46a 
substitute for the resected oesophagus. The anastomosis is placed in the upper 
thorax with transthoracic surgery, and in the neck with the transhiatal approach45. 
Four randomized controlled trials47-49 and two meta-analyses50,51 have been 
published, results showed that both techniques have a similar rate of complications 
and long term outcome35. Likewise both approaches are cancelled if metastases are 
found (sometimes called “open and close surgery”) and both include surrounding 
tissue in the surgical specimen45. During surgery, lymph nodes in two-fields, 
around the abdomen and lower half of the chest are removed. Some countries, such 
as Japan, also perform an extensive cervical lymphadenectomy (three-field) 
although long term HRQL is affected, and any benefits of such extensive node 
dissection are uncertain11,52,53. Studies on minimal invasive oesophagectomy, 
(exclusively scope resections), have suggested less risk of anastomotic leaks and 
faster postoperative recovery. Randomized controlled trials are, however, lacking54. 
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Postoperatively 
The patient usually initially stays in the intensive care unit and is then cared for at a 
surgical ward. Oesophagectomy is one of the most extensive elective surgical 
procedures. Rates of deaths during surgery or close after are 4-10% and about 26-
47% of the patients suffer from major morbidity within the first 30 days12,13,55. 
Complications in the SECC-registry were in declining order55: respiratory 
insufficiency, cardiac complications, serious infection, technical, (postoperative 
bleeding, reoperation, damage to the recurrent laryngeal nerve or thoracic duct), 
leakage of anastomosis or necrosis in substitute, early anastomotic stricture with 
severe dysphagia needing intervention and others. Postoperative care is continuous 
for about three years, usually with check-ups after 3, 6, 9, 12, 18, 24 and 36 
months.  
 
Postoperative Adjuvant Therapy 
Postoperative radiotherapy has been debated. Regarding survival, cases of shorter 
survival due to irradiation-related deaths such as bleeding gastric ulcers56, similar 
survival but fewer recurrences57, as well as longer survival for patients with over 
three positive lymph nodes58 have been reported. Results for radiotherapy 
compared to chemotherapy were similar59. 
 
Recurrences 
Recurrences develop quickly; six months after surgery about 8% of the patients 
have already developed a recurrence and approximately every third patient, 
irrespective of histological type, suffered a recurrence within one year11,12. The 
survival time after a recurrence is usually only a few months11. Recurrences are 
likely to appear locally in the mediastinum and upper abdomen or distantly through 
haematogenous spreading to the liver, skeleton or other places11,60. Cervical 
recurrences are rare11,60. 
 
Palliative Treatment 
Since at least 50% of the patients are not suitable for curative treatment13 at the 
time of diagnosis, palliative treatment is of great importance. Examples of goals for 
such treatment could be to relieve dysphagia or to preserve HRQL27,61-63.  
Since recurrences after curative treatment are common and second-line treatments 
are sparse, palliative care plays an important role even in patients’ undertaken 
curative-intended treatment. 
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QUALITY OF LIFE 
The Concept of Quality of Life 
No generally agreed-upon definition of ´quality of life´ exists, and many of us seem 
by intuition to see quality of life as an abstract evaluation of central values of life or 
as “the essence of existence” without needing any definition64. The term quality of 
life can be found in several different disciplines, for example it has referred to “the 
good life”, meaning her life is not bad for herself among philosophers since 
Antiquity, while in psychology it refers to the mental state, in sociology to welfare 
and in economics to the gross domestic product64,65. Furthermore, how the term has 
been defined and measured has also changed over time; after the Great Depression 
in 1930 western cultures evaluated if people were well fed, educated and worked 
fewer hours, while in the 1960s individual happiness was more important65. In 
1948 the World Health Organisation introduced a wider concept of health by 
defining it as “a state of complete physical, mental and social well-being, and not 
merely the absence of disease”. Afterwards, medical researchers have diverted their 
interest to patient-reported outcomes65, meaning any report coming directly from 
the patient about a health condition and its treatment without the intervention of an 
observer66. The present thesis does not evaluate patient-reported outcomes in this 
broad perspective, but it relates to symptoms and functions that might be affected 
by disease or medical treatment, which corresponds to “health-related quality of 
life”, HRQL. This term highlights that the person is a patient and the focus is 
burden of  disease. Most definitions of HRQL agree that “HRQL is a 
multidimensional construct which encompasses patients´ perceptions of both 
negative and positive aspects of at least four dimensions; physical, emotional, 
social functions as well as disease and treatment related symptoms”67. Although 
the palette of definitions is exhaustive enough to suit even the most discerning 
researcher, many skirt around a definition by letting the meaning of HRQL 
instruments intuitively be understood without stating a definition67. 
  
The Concrete Nature of HRQL  
When reducing the term HRQL to a concrete level, it often assess symptoms and 
functions in a subjective way that can only be understood from the patient’s point 
of view. The word symptom derives from the Greek σύμπτωμα, meaning 
misfortune or accident, while the Latin word sympthoma refers to indication or 
sign68,69. Previously and still today, symptoms differ from signs. Signs are more 
objective and observable such as body temperature, while symptoms are the 
patients’ subjective evidence of disease and their expression of it, such as having 
pain70. Professional care providers often view symptoms as disease (progress) 
indicators or side effects from treatment, and symptoms are therefore used as an 
empirical guide to diagnosis70-72. They might find interest in symptom occurrence 
(frequency, duration, intensity) and its distress (degree of discomfort)70. Patients, 
on the other hand, might talk about symptoms as reminders of a lethal cancer72 and 
sensations or symptoms with consequences for their daily life70. The daily life 
consequences might be difficult to capture merely by symptoms, therefore HRQL 
often also assesses functions as a measure of the more complex compound of 
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symptoms affecting the ability to lead a normal, everyday life. Even if the functions 
and symptoms objectively appear to be similar within or between patients, the 
burden can still be experienced differently. It is assumed that this is due to a 
perceptual process with individual selection dependent on both body and 
mind70,71,73,74. In a cancer patient, this might be exemplified by metastases 
producing a constant level of factors affecting pain receptors, but the number of 
symptoms reported by the patients depends on personality, genetic disposition, 
learned response etc. The individual influences on HRQL have been described both 
as the widely-used conceptual model by Wilson and Cleary in 1995 and as 
response shift by Sprangers in 199675,76. 
 
HRQL as a Conceptual Model  
In 1995, Wilson and Cleary constructed a model that integrates biological and 
psychological aspects of health and their relationship with HRQL outcomes75. The 
aim was to unite biomedical paradigms, focusing on etiological agents for 
therapeutic grouping of patients and the social science paradigms with an all-
encompassing focus, particularly on the contribution of social structures to 
illness75,77. The model has been considered valuable since it both emphasises that 
quality of life is just one component of possible outcomes, and it stresses that 
health is not physical status without patient input77,78. 
Figure 2. Conceptual model by Wilson and Cleary of factors influencing patient outcomes 
such as HRQL. Adapted with permission from “Linking clinical variables with health-
related quality of life. A conceptual model of patient outcomes.” 273(1):59-65. 
Copyright© 1995 American Medical Association. All rights reserved. 
 
Simplified, the model describes five levels of subjective outcomes. Starting at the 
left on a cell level with biological and psychological variables and moving right to 
an individual level with symptom status (e.g. cognitive and physical symptoms), 
moving on further to the right, where the individual is integrated as a member of a 
society by demanding a functional status (e.g. physical, social, and psychological 
functioning). The general health perception is a subjective evaluation, integrating 
all the precedent outcomes and generating overall quality of life as an interpretation 
of how satisfied a person is with her life at large.  
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HRQL and Individual Influences 
Along with the exploration of conceptual models, other individual influences on 
HRQL are sought for. Differences in HRQL between people have been explained 
by differences in lifestyle79 and genetic variations, e.g. regarding pain and fatigue80. 
An interesting ongoing project is the international GENEQOL Consortium81, which 
intends to investigate the genetic disposition of patient-reported quality-of-life 
outcomes. Five important quality-of-life outcomes have been identified as initial 
targets; negative psychological affect, positive psychological affect, self-rated 
physical health, pain and fatigue. The goal is to identify biological pathways, genes 
and genetic variants in order to detect patients’ susceptibility to poor quality of life 
and consequently target interventions. This is more than likely only the threshold of 
a new era in HRQL research.  
 
 
Response Shift- Changes over Time 
When measuring HRQL longitudinally 
in patients, who are faced with a major 
event such as cancer surgery, it might 
be difficult to know what to compare 
the data with. Patients might for 
example calibrate their own scale based 
on previous health conditions or 
personal priorities. This change in 
interpretation of the meaning has been 
described as response shift. Response 
shift was first described in educational 
research76,82,83 as changes in the 
meaning of a target due to recalibration 
of internal standards, reprioritizing of 
values and reconceptualisation of its 
construct. ‘Recalibrations’ can be 
exemplified by  
a patient’s experience of the severest possible pain before surgery, whereas after 
surgery that pain was reconsidered to be only mild compared to the severity of the 
postoperative pain. ‘Reprioritization’ means that a cancer patient with poor 
prognosis might not find interest in maintaining good physical function compared 
to maintaining emotional or social functions. ‘Reconceptualisation’ means that 
patients might change beliefs in life such as being religious close to the end of their 
lifetimes. The phenomenon ‘response shift’ was described as a model in 1999 by 
Sprangers et al83.  
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Figure 3. Theoretical model of response shift developed by Sprangers and Schwartz 1999. 
Reprinted with permission from Social Science and Medicine, 48, 1507-1515, Copyright© 1999, 
Elsevier Science.  
 
This model suggests that whether or not a change in health status (catalyst) is 
reported in HRQL (perceived QOL) is based on patient characteristics 
(antecedents), such as education (sociodemographics) and personality. In 
conjunction with coping strategies and social support (mechanisms), they are input 
for a self-evaluation (response shift) of the changed status before it is reported. 
Response shift is hypothesised to occur more often in patients, who improve or 
deteriorate since they, in contrast with stable patients, are expected to re-evaluate 
their situation. A meta-analysis of the effect size indicated that it seems to be 
relatively small but may result in underestimation of true change in quality of life84. 
The largest effect has been found for global quality of life, physical function, 
fatigue and pain84,85 
 
A combination of the facts presented above emphasises why HRQL could never be 
measured objectively; its intrinsic value lies in its subjectivity. 
  
The Rationale for HRQL in Clinical Research  
In medical care, treatment is offered with three main aims 1) to increase longevity, 
2) to prevent future morbidity and 3) to make the patients feel better78. In the last 
decade outcomes related to aim three, such as impact of treatment on HRQL, have 
become standard practice in high quality clinical cancer trials65,67. HRQL has been 
found valuable in palliative care, when cure is no longer possible, as the balance 
power when two treatments achieve main results of equal value67,86,87. One example 
is that survival was similar but HRQL was better preserved if radiotherapy was 
given continuously rather than intermittently in advanced breast cancer patients88. 
HRQL assessments have also revealed the need for treating radiotherapy-induced 
fatigue with physiotherapy89. Moreover, a review found associations between 
HRQL and survival, suggesting that HRQL is a prognostic marker90. Finally, 
patients expect to receive a realistic individual prognosis91 and feel a need to 
discuss HRQL with their physician92.  
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Instruments for measuring HRQL 
HRQL can be assessed through existing or study-specific interviews or 
questionnaires. The questionnaires might be terminal-based or printed and 
preferably filled in by the patient himself but if necessary by proxy. The existing 
instruments can be grouped as67  
• Generic – measure broad aspects of health independent of illness; examples 
are Medical outcomes Study-36 item short form (SF36) and Schedule for 
individual evaluation of quality of life (SEIQoL). 
• Disease-specific – focus on disease specific issues; examples are European 
Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 
and Functional Assessment of Cancer Therapy (FACT-G). 
• Aspect-specific – focus on certain aspects independent of other conditions; 
examples are Hospital Anxiety and Depression Scale (HADS) McGill Pain 
Questionnarie (MPQ) and Multidimensional Fatigue Inventory (MFI). 
 
Considerations before Choosing Instrument 
An instrument needs to be selected, depending on the purpose of the trial93, e.g. if 
HRQL is a primary or secondary endpoint and which aspects (generic, disease, 
single symptom or treatment) are to be evaluated. It is important to bear in mind the 
study respondent’s level of education, age range, language and cultural variations, 
in conjunction with the burden of assessments. Practical issues such as timing and 
frequency of assessments in relation to resources available, as well as procedures 
for missing answers, need to be considered86. Psychometric properties are of great 
importance and have four independent, important basic fundaments, which 
interrelate67. 
 
• Validity – Does the instrument measure what is wanted in a sensible 
manner? If it measures what is wanted, it might be evaluated by experts as 
comparisons with other known instruments and as correlations within or 
between other scales in the instrument. In a subjective instrument, as when 
measuring HRQL, validity can include the instrument correlating with other 
more observable events and behaving as anticipated67.  
• Reliability –Is the result random or reproducible, meaning would one patient 
produce the same answer to the same question every time if her condition 
remains unchanged? 
• Sensitivity –Are differences between patients or groups that are believed to 
exist detected, e.g. differences between patients with a different health 
status? 
• Responsiveness –Are changes over time within a group or individual 
detected if they improve or deteriorate?  
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DEFINITION OF HRQL AND 
RATIONALE FOR CHOSEN INSTRUMENTS 
In this thesis, HRQL has not been clearly defined a priori, instead it has been 
assessed through two commonly used disease-specific questionnaires, EORTC 
QLQC30 and EORTC QLQ-OES18.  
Some arguments substantiate this choice of instrument; since HRQL was a main 
endpoint it should have solid documentation and assess both general cancer issues 
and oesophageal cancer-specific issues. Since the majority of the patients were 
most likely to be middle-aged it was important to have a validated translation of the 
questionnaire in Swedish, while still being of international use. Other benefits were 
the inexpensive and easy administration.   
 
 
THE EUROPEAN ORGANISATION FOR RESEARCH AND 
TREATMENT OF CANCER (EORTC) AND ITS 
QUESTIONNAIRES 
EORTC is an international grant-supported organisation initiated in Belgium in 
1962 by oncologists from the EU countries and Switzerland. Their aim is to 
develop, conduct, coordinate and stimulate translational and clinical research in 
Europe94. Their quality-of-life group developed an integrated measurement system 
for clinical trials in 1986. A modular approach was adopted to ensure 
generalisability while still enabling questions relevant to particular groups of 
patients. The result was a core questionnaire assessing HRQL issues relevant to 
most cancer patients (QLQ-C30) and several cancer-specific modules including 
oesophageal cancer (QLQ-OES18).  
The questionnaires assess HRQL multidimensionally and are designed for self-
administration in cross-culture settings94. They include both single items answering 
one single aspect, such as constipation–Have you been constipated? and multi-item 
scales consisting of several questions for complex symptoms such as fatigue – Did 
you need to rest?,- Have you felt weak?  -Were you tired? All questions refer to the 
past week.  
The questionnaires have been translated into several languages, including Swedish, 
and involve translations by two independent native speakers95.  
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The General Cancer Core Questionnaire - QLQ-C30 
QLQ-C30 was developed in 1987 and since then five versions with slight 
differences (mainly adding hobbies to role function and changed response 
alternatives for physical function) have been evolved. It has been translated into 81 
languages and used in over 3000 studies94,95. For comparison purposes, reference 
values, stratified for age and sex from the general Swedish population, exist; see 
page 3296.  
 
Information 
The latest version (3.0) contains 30 questions (q) giving nine scales and six single 
items (see appendix): 
• Global quality of life scale (q29-30). 
• Functional scales: physical (q1-5), role (q6-7), emotional (q21-24),  
cognitive (q20, 25), and social (q26-27). 
• Symptom scales: fatigue (q10,12,18), nausea & vomiting (q14-15) and pain (q9, 
19).  
• Single items: dyspnoea (q8), insomnia (q11), appetite loss (q13), constipation 
(q16), diarrhoea (q17) and perceived financial impact by disease (q28). 
The responder is asked to answer the question based on the past week. Each 
question has four possible response alternatives: 1) “Not at all” 2) “A little” 3) 
“Quite a bit” 4) “Very much”. Global quality of life has a seven-grade scale rising 
from 1) “Very poor” to 7) “Excellent”. 
 
Psychometric Properties  
Several tests of psychometric properties have been performed with satisfying 
results97-102. The initial version (1.0) was tested on 305 lung cancer patients from 13 
countries and the alternations in the latest version (3.0) were tested in 2000 among 
622 head and neck cancer patients from 12 countries101. Validity was tested as 
correlations between scales. The results showed that global quality of life 
correlated with most scales. Likewise fatigue correlated with most scales after 
treatment. And as expected, physical function correlated with role function both 
before and after treatment. Likewise pain correlated to social function after 
treatment. But, to conclude, the questionnaire was stated as a valid measure of 
HRQL among cancer patients. Regarding clinical validity, disturbed emotional 
function was found among patients with metastatic disease and, as expected, 
associations were found with performance status, weight loss and treatment 
toxicity. Reliability for scales was assessed with Cronbachs alpha. The results 
showed a skewed distribution towards maximum function for cognitive and social 
functions. Furthermore, uncommon symptoms in lung cancer patients (diarrhoea 
and constipation) were rare. The reliability was stated as good (>0.7) for pre-
treatment global quality of life, emotional function, fatigue and pain and for all 
post-treatment items expect for role function. The reliability was improved for the 
changed physical function in version 3.0101. 
Responsiveness was addressed such as changes over time, which was found for 
patients with changed performance status.  
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The Oesophageal Specific Questionnaire QLQ-OES18 
QLQ-OES18 assesses issues specific for oesophageal cancer. The first version, 
QLQ-OES24, was published in 1996 and developed based on interviews with 
patients, health care providers and literature103. 
 
Information 
The questionnaire includes 18 questions (q) forming four scales and six items (see 
appendix) with response alternatives as for QLQ-C30: 
• Symptom scales: dysphagia (q31-33), eating difficulties (q36-39), reflux (q44-
45), oesophageal pain (q46-48),  
• Single items: trouble swallowing saliva (q34), choking (q35), dry mouth (q40), 
taste problems (q41), coughing (q42), speech difficulties (q43). 
 
Psychometric Properties 
During the validation, published in 2003, on 591 oesophageal cancer patients from 
six countries, questions about burping and hair loss were withdrawn and the 
questionnaire was revised to QLQ-OES18104.  
Validity was tested as correlations to the QLQ-C30 scales. Results showed that 
correlations were generally low (Pearson’s r <0.4) except for oesophageal pain, 
which, as expected, correlated to the QLQ-C30 pain score and eating difficulties 
correlating to social function and fatigue.  
Clinical validity was tested presuming the questionnaire could detect differences 
between groups of curative and palliative patients. Results showed that patients 
with curative-intended treatment scored significantly better at baseline than 
palliative patients. Patients who had undergone an oesophagectomy reported poorer 
postoperative social function and more nausea but less dysphagia than other 
patients.  
Reliability was assessed with Cronbachs alpha, and stated as good (above 0.7) in 
60% of the scales. The highest value was found for eating difficulties and 
dysphagia scales while reflux and pain showed weaker results. 
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Interpreting the Results from EORTC Questionnaires 
To evaluate results from EORTC questionnaires in a context, results could be 
reported in several ways (e.g. as raw scores and transformed scores see, page 43): 
comparing results to other published data or using cut-offs based on “clinical 
significance”105. In HRQL, research terms such as “clinical relevance” or “clinical 
significance” have gained ground as initial cut-offs, followed up by a statistical cut-
off before results are approved67. Both cut-offs complement each other, statistical 
significance determines if our results can be explained by chance fluctuations alone 
but statistical significance can easily be found in a large sample without having any 
clinical meaning for the patients67. Although clinical significance is subjective67, 
the minimal clinically important difference has been defined as the smallest 
difference patients notice as beneficial, and a change that would cause clinicians to 
consider a change in the management of the patient67. Two general approaches to 
interpreting the minimal clinically important difference are described in EORTC’s 
scoring manual105: the anchor-based approach below, meaning comparison of 
HRQL scores with clinical changes or results, and the distribution-based approach, 
meaning comparisons based on statistical distribution of result. The anchor-based 
method is recommended if possible106,107. 
 
Anchor-based Method 
Two milestone studies have evaluated the clinically relevant cut-off value on QLQ-
C30. The study most referred to was performed by Osoba et al in 1998108. In that 
study, breast and lung cancer patients filled in the QLQ-C30 once prior to and 
twice following chemotherapy, along with a subjective significance questionnaire 
asking the patient “Since last time I filled out a questionnaire, my global quality of 
life/physical/emotional/ social function is…; response options ranged from 1) 
“Very much worse” to 7) “Very much better”. Conclusions were that on a 0-100 
scale, a 5-10 point shift corresponded to a slight change, a 10-20 point shift to a 
moderate change, and a shift of more than 20 points corresponded to considerable 
change. Earlier, King109 had performed a retrospective study, in which she 
compared clinical changes in performance status, weight loss, toxicity and severity 
of disease to HRQL scores from 14 studies; she found that on a 0-100 scale, a 
change in 5 points was interpretable as a relativelysmall change whereas 15 points 
corresponded to a relatively large change109. She concluded that a difference of 10 
points in mean score may in clinical settings represent significant symptom control. 
Furthermore, the level of 10% has also been found by other researchers93,110,111 and 
gained acceptance as clinically relevant67. 
 
Distribution-based Method 
The distribution-based method might be useful when patient-data or reference data 
are lacking although they are based on the actual distribution of results. Either the 
between-patients variability (standard deviation of patients baseline), or the within-
patients variability (standard deviation of change over time)93,105 can be used. In the 
study by Osobas et al108, the results were in line with the results from the anchor-
based method. 
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Presenting the Results from EORTC Questionnaires 
A common post-treatment comparison level is baseline HRQL, measured before a 
course of treatment is to be decided on or induced. Ideally, baseline would be 
before the disease has developed but this is not feasible in clinics. As a surrogate, 
baseline HRQL can be expected to be similar to that of the corresponding general 
population. Scores from the general population in Sweden published in 2000 are 
presented in Table 3 to give an indication of expected “normal” values in QLQ-
C30. No such data exists for QLQ-OES18. 
 
Table 3. Reference values for males and female in the age group 60-69 years assessed 
among the Swedish general population96. The scale range is from 0 to 100. A high score 
on functioning scales and global quality of life corresponds to a good function, while a 
high score on symptoms corresponds to many symptoms. 
 Male reference 
60-69 years 
Female reference 
60-69 years 
 Mean score  
N=278 
Mean score 
N=271 
Global Quality of life 
 
77 78 
Functioning scales   
Physical function 88 87 
Role Function 87 87 
Emotional function 86 84 
Cognitive function 87 90 
Social function 
 
91 92 
General symptom scales   
Fatigue 20 20 
Nausea & Vomiting 2 3 
Pain 
 
18 21 
General symptom items   
Dyspnoea 19 16 
Insomnia 17 23 
Appetite loss 2 4 
Constipation 4 9 
Diarrhoea 5 4 
Financial difficulties 5 7 
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BIOLOGICAL MECHANISMS FOR CANCER SYMPTOMS 
 
General Cancer Symptoms 
Biological mechanisms for common symptoms are poorly understood and interact 
in a complex way. To illustrate, two common symptoms - fatigue and pain - will be 
discussed. Fatigue has been associated with levels of proinflammatory cytokines 
(IL1, IL6, TNFa) probably due to tissue damage and cell death80,112. Likewise, 
treating anaemia has been suggested to be of major importance for quality of life 
outcomes including fatigue113-115. Nutritional factors such as alternation in abilities 
to process nutrients, increased energy requirements and decreased energy intake 
and closely related cancer anorexia and cachexia are possible reasons for fatigue1-
3,29,116. Furthermore, stress, anxiety and depression are the most common 
comorbidities of fatigue117. Finally, cancer patients might acquire an altered 
circadian rhythm resulting in changed social function, increased fatigue and pain, 
as well as shorter survival118. Pain is commonly present among 55-95% of terminal 
cancer patients119, possibly due to metastases resulting in local ischemia, nerve 
pressure and inflammation. Interestingly, the severity of pain has been studied, and 
certain gene expressions seem to be associated with greater needs of pain killers80. 
Furthermore, pain it self might cause nausea via connections to the autonomic 
nerve system. Lately, the term clustering, meaning coexistence of more than three 
symptoms such as pain, fatigue and poor appetite, has evolved as a concept120. It 
has been suggested that symptom clusters might have an adverse effect on patient-
reported outcomes and a synergetic effect on predictors of morbidity120.  
 
Oesophageal Specific Symptoms 
Common symptoms for operated oesophageal cancer patients are typically related 
to eating, and about 4-68% of the patients suffer a certain mixture of symptoms 
called early dumping121,122. Early dumping is due to the lack of vagal reflexes (after 
vagotomy) which accommodate, relax and empty the stomach, resulting in a raised 
pressure gradient from the stomach to the intestine. In conjunction with the 
removed portioning mechanism of the antrum and pylorus, this results in premature 
gastric emptying122,123. Early dumping includes symptoms such as nausea, 
vomiting, cramping stomach pain, flushing, heartbeat, vertigo and diarrhoea about 
30-60 min after intake of food. In contrast, patients might also suffer from 
constipation due to opiates, postoperative weaknesses of bowel muscles and intra-
abdominal adherences. Furthermore, operated patients have a smaller gastric 
volume, resulting in increased gastric wall tension after eating a normal meal, 
which results in fatigue, feeling full, nausea and premature satiety. Problems with 
eating and dysphagia postoperatively might be due to an anastomotic stricture, and 
reflux is due to the excision of the lower oesophageal sphincter and distorting 
anatomy.   
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HRQL IN CURABLE OESOPHAGEAL CANCER PATIENTS 
 
Patient and Tumour Characteristics 
Baseline scores for patients with planned curative treatment are in general typically 
good for functional scales, although patients are likely to report problems with 
fatigue, pain, insomnia, appetite loss, dysphagia, eating difficulties, reflux, 
oesophageal pain, dry mouth, taste problems and coughing6,124. Regarding patient 
characteristics, long term scores have been similar for sexes, but dumping might 
occur more often among women and younger patients125 , younger patients might 
also have poorer emotional function125,126.  
To the best of my knowledge, no studies have primarily investigated differences 
between BMI-groups or influence of comorbidities on HRQL among cancer 
patients.  
Regarding tumour characteristics, patients with a more advanced tumour stage have 
poorer global quality of life and social function, more fatigue and appetite loss127 
compared to less advanced stages. One difference has been found between 
histological types, namely more pain among patients with SCC than those with 
AC128. Furthermore, in one study patients with SCC were more likely to be selected 
for chemoradiation than neoadjuvant therapy and surgery. The chemoradiation 
group generally had worse baseline functions and more dysphagia but deteriorated 
less during treatment124.  
 
Treatment Related Factors, Recovery and Recurrences 
Curative treatments have at least a short negative influence on HRQL6,124,126,128-135. 
Clinically relevant differences at baseline between patients selected for curative 
surgery versus palliative patients have been shown regarding global quality of life, 
physical function, role function, social function, fatigue, pain, dysphagia, trouble 
swallowing saliva and dry mouth104.  
Regarding the surgical approach, patients undergoing transhiatal surgery recover 
their physical function earlier than those with a transthoracic approach129. Patients 
with a cervical anastomosis report better physical and social function and less 
reflux than those with a thoracic anastomosis125,136. Patients with a junctional AC 
report better global quality of life, role and social function and less fatigue if they 
are treated with total gastrectomy rather than transthoracic oesophagectomy133.  
Surgical factors, such as surgeon or hospital volume, do not seem to influence 
HRQL negatively137,138.  
Postoperative complications such as reoperation, anastomosis leakage, infections or 
respiratory insufficiency affect physical and role function, while infections and 
cardiac complications negatively affect the global quality of life138. Interestingly, 
fatigue and dyspnoea at baseline have been found predictive for in-hospital 
mortality and major complications, although no differences regarding either history 
of respiratory disease or in the test for pulmonary function could be found between 
groups134.  
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The recovery period for HRQL outcomes seems to be somewhere between six to 
twelve months from baseline6,124,130-132,139,140. HRQL scores on a 100-point scale are 
worst at six weeks postoperatively with a reduction of at least 30 points in mean 
score for physical function, role function, social function and at least a 15 point 
increase in mean score for fatigue, nausea and vomiting, dyspnoea, diarrhoea, dry 
mouth, taste problems and coughing124,132.  
Patients who suffer from tumour recurrence report poorer HRQL and never recover 
to baseline130,141, although it is unclear how early recurrences can affect HRQL and 
early recurrences have so far only been shown to affect constipation134.  
 
Overall Survival and Long term HRQL 
In all, eight studies have evaluated associations between baseline HRQL and 
survival127,134,135,142-146. Baseline physical function was predictive in five studies, 
fatigue in two studies, while the following outcomes were predictive in one study 
each: global quality of life, role function, social function, reflux and appetite loss90. 
One study found that an improvement in emotional function from baseline to post-
treatment was associated with better survival143.  
Likewise, postoperative scores for social function, dysphagia and pain have been 
found prognostic for survival135,147 .  
Longer term follow-ups, i.e. two to five years, have shown that patients might 
almost regain their HRQL, but certain aspects are more prone to remain negatively 
affected, such as global quality of life, physical function and role function, as well 
as symptoms from fatigue, reflux and diarrhoea, from which they might not fully 
recover6,124,126,129,130,148. However, emotional function has actually been shown to 
improve, while dysphagia decreases, especially in survivors6,128,143.  
  38 
 
  
    39 
THE AIMS OF THE STUDIES 
 
  
The overall aim of this thesis was to identify influences HRQL, and to clarify 
whether HRQL can predict morbidity and survival among patients operated on for 
oesophageal cancer.  
 
To be able to accomplish the overall aim, the following specific aims were 
formulated: 
 
I) To clarify which deteriorated postoperative HRQL outcomes are to be 
considered transient with time after surgery, and which are long-
standing.  
 
II) To establish the influence of specific patient characteristics (age, sex, 
BMI and comorbidity) and tumour characteristics (location, histological 
type and stage) on postoperative HRQL. 
 
III) To elucidate the prognostic value (chance of long term survival) of 
changes in HRQL-scores before and after surgery.  
 
IV) To ascertain the prognostic value (chance of long term survival) of 
HRQL-scores assessed six months after surgery.  
 
 
 
 
The aims were stated in order to: 
 
• Find clinical warning signs for poor prognosis.  
• Increase knowledge for improvement of clinical follow-ups. 
• Facilitate basic data for informed consent treatment. 
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MATERIAL AND METHODS 
 
DESIGN AND DATA COLLECTION 
This thesis uses clinical data from two research databases. Studies I, II and IV are 
based on the nationwide Swedish Esophageal and Cardia Cancer registry (SECC-
registry), while Study III derives from the British single centre Upper 
gastrointestinal database. An overview of the designs, data collection and methods 
used are presented in Table 4. 
 
 Table 4. Overview of material and methods in the four studies. 
 
 Study I Study II Study III Study IV 
Design Prospective cohort 
Source 
population 
Sweden’s population Avon, Somerset 
and Wiltshire 
area 
Sweden’s 
population 
Cohort SECC-registry Upper 
gastrointestinal 
database 
SECC-registry 
Exposure Curative 
surgery for 
oesophageal 
cancer 
Patient and 
tumour 
characteristics 
Changes in 
HRQL-scores 
from before to 
after treatment 
Postoperative 
HRQL-scores  
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COHORT 
 
The Swedish Esophageal and Cardia Cancer Registry 
 
Background 
Studies I, II and IV were based on a nationwide clinical data collection from 
patients who underwent surgical resection for oesophageal or cardia cancer in 
Sweden during the period April 2001 to December 2005. This research database 
was entitled Swedish Esophageal and Cardia Cancer Register (SECC-registry) and 
was based on a Swedish network of hospital departments involved in the diagnosis 
and treatment of oesophageal and cardia cancer patients. Virtually all (175 out of 
179; 97%) of the eligible hospital departments in general surgery, thoracic surgery, 
oto-rhino-laryngology, oncology and pathology have participated. Around 90% of 
all surgically treated oesophageal cancer patients in Sweden have been 
prospectively included and followed up149. A total of 616 patients was included in 
the register until the stop date for inclusion of new patients in December 2005. The 
organisation behind the data collection was originally created as a population based 
case-control study concerning risk factors for oesophageal and cardia cancer149, 
whereas it was later (in 2001) directed towards clinical research.  
 
Data Collection 
The registry was coordinated and administrated by a central project manager (Eja 
Fridsta), who was the key person in the data collection. All data were collected by 
starting off with a histopathology report on a confirmed oesophageal or cardia 
cancer from the pathology department and thereafter contacting physicians for 
informed consent from the patient and retrieval of individual data. Non-
participating clinics and missing informed consents, mainly due to physicians not 
asking patients, explained the missing data on 10% of the patients. Based on a 
detailed study protocol, the collected data was thoroughly reviewed via manual 
scrutiny of medical reports by a handful of clinicians and researchers in our group. 
Variables such as tumour characteristics (site, stage and histological type), 
preoperative physical examinations, comorbidities, neoadjuvant treatment, surgical 
treatment, complications, length of hospital stay, and place of discharge were 
collected. The database contains HRQL measurements, assessed postoperatively 
six months, three years and five years after surgery. 
 
Validity and Reliability  
Certain aspects within the registry suggest good validity and reliability. The high 
national coverage, and the detailed manual data collection performed prospectively 
by researchers, not personally involved in the treatment of the patients, are among 
the methodological advantages. Another important advantage was that the 
collection of HRQL data was obtained anonymously, i.e. the patients sent their 
answers to an unknown central registry, and not to their physician or hospital 
department.  
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The Upper Gastro-Intestinal database in Bristol, U.K. 
 
Background 
Study III is based on the database described below. The United Bristol Healthcare 
Trust in southwest Britain started a prospective cohort named the Upper 
gastrointestinal database in November 2000.  
Patients were recruited from a total population of 1.66 million150 and included in 
the Avon, Somerset and Wiltshire Cancer network.  
The aim of the database was to collect a prospective research database for upper 
gastrointestinal cancers such as oesophageal, cardia, gastric, liver and pancreas. 
Totally, 216 oesophageal cancer patients were included in the database when I 
started my work on it. 
 
Data Collection 
After referral to the participating hospitals the patients were asked for informed 
consent. Patients were asked for socio demographics and HRQL data either in 
hospital or in conjunction with a home visit, while the clinical data such as tumour 
characteristics (site, stage and histological type), preoperative physical 
examinations, comorbidities, neoadjuvant treatment, surgical treatment, 
complications, length of hospital stay, and place of discharge were gathered by 
means of a manual review of records.  
A first HRQL assessment was performed in hospital within 30 days prior to surgery 
or up to 9 days after initiating non-surgical treatment. This first HRQL assessment 
was labelled baseline HRQL.  
Follow-up data were collected six weeks, then 3, 6, 9, 12, 18, 24 and 36 months 
after the operation.  
 
Validity and Reliability 
Data on participating patients was almost complete and missing data was rare, 
which increases the internal validity. Furthermore, the prospective data collection 
was based on a predefined protocol, which increased validity and reliability. 
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HRQL MEASUREMENT  
In all four studies, HRQL measurement has been carried out using the two 
questionnaires (QLQ-C30 and QLQ-OES18) developed by the EORTC and 
described in the background (pages 29-30) and attached in the appendix. There has 
been a hypothesis-driven and literature-based6,127,131,134,135,144,146,147,151 selection of 
outcomes to minimize multiple testing as presented in Table 5.  
 
Table 5. List of selected outcomes from the EORTC QLQ-C30 and QLQ-OES18 per 
study.  
STUDY I II III IV 
Global  
Quality of life 
 
● 
 
● 
 
● 
 
● 
 
Functioning scales 
Physical ● ● ● ● 
Role ● ● ●  
Emotional ● ● ● 
Social ● ● ● ● 
Cognitive ●  ● 
 
General cancer symptoms 
Fatigue ● ● ● ● 
Nausea ● ● 
Pain ● ● ● ● 
Dyspnoea ● ● ● ● 
Insomnia ● ●  
Appetite loss ● ● ● ● 
Constipation ● ● 
Diarrhoea ● ● ● 
Financial impact ● ● 
 
 
 
 
 
 
 
 
 
 
Time Frame and Performance of HRQL Assessments 
Patients in the SECC-registry have answered the questionnaire in Swedish. It was 
sent per mail to their home address after informed consent and up to three 
reminding letters were sent out, if appropriate. The time window both for the 
assessment after six months in Studies I, II and IV, as well as for the three years’ 
assessment used in Study I was +/- three months. In the Upper gastrointestinal 
database, patients filled in the questionnaire while hospitalised or at home, and if 
needed, one reminding telephone call was made. If data were still missing, patients 
were telephoned for additional responses. The baseline and six months’ follow-up 
were used in Study III. The time window for the baseline was within 29 days 
before initiation of therapy, and for chemoradiated patients up to 9 days after the 
start of treatment. The time window for the six months’ assessment was 180 days (-
56/+48 days). 
 
 
STUDY I II III IV 
Oesophageal cancer symptoms 
Eating difficulties ● ● 
Reflux ● ● 
Oesophageal pain ● ● 
Dysphagia ● ● ● 
Coughing ● ● 
Dry mouth ● 
Taste problems ● 
Choking ● 
Speech difficulties ● 
Trouble swallowing 
saliva 
 
● 
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Scoring, Interpretation and Presentation 
EORTC’s QLQ-C30 scoring manual105 declares that results 
can be reported in several ways e.g. as raw scores (response 
alternatives 1,2,3,4) or transformed scores. Transformation of 
the raw answers occurs according to the formula below105,152: 
 
1) The raw answers are transformed to a raw score (RS) by: 
RS= (answer1+ answer2+…+answern)/n 
n= number of question within a scale 
 
2) Linearly transformation from RS to score(S) between 0-100. 
For functional scales: S= (1- ((RS-1)/range) *100 
Global quality of life and symptom scales/items: S= ((RS -1)/range) *100 
 
Studies I and III 
All responses were transformed to a score between 0-100 according to the scoring 
manual. A high score on functional scales and global quality of life represented a 
high level of function and better quality of life, whereas a high score on symptoms 
indicated more symptoms. A difference of at least 10 points between different time 
points or between patients was considered to be of clinical relevance in accordance 
with previous literature108,109. In Study I, mean scores were compared to age-and-
sex matched strata of the Swedish general population. 
 
Studies II and IV 
In Studies II and IV responses were dichotomised. The cut-off was based on 
clinical relevance, meaning a response of at least 3 “Quite a bit” would make a 
clinician react. Patients who responded with at least one 3 “Quite a bit” or  
4 “Very much” to any item within a functional scale were categorised as having 
“Poor function”; otherwise, patients were categorised as having “Good function”. 
Likewise, answers on the symptom scales and items were dichotomised into 
“Symptomatic” if the patient produced at least one response of 3 “Quite a bit” or 4 
“Very much” otherwise patients were dichotomised into “No or minor symptoms” 
(except for the dysphagia scale with an opposite response direction). A response of 
4 or less (i.e., worse than the mean score of the total group) to either of the two 
questions on the global quality of life scale, was considered to represent a “Poor 
global quality of life”; otherwise, the patient was considered to have a “Good 
global quality of life”.  
 
Missing Data 
Missing items were treated according to the scoring manual105 and were not 
imputed or estimated; instead if a patient for example did not respond to dyspnoea, 
he was excluded from analyses of dyspnoea but included in all other analyses of 
functions and symptoms. Regarding multi-item outcomes, patients were included if 
they had answered at least half of the questions and the answers were then divided 
by the number of answered questions. 
Range is the 
difference between 
maximum (4) and 
minimum (1) possible 
response alternative.  
All questions, thus 
have range 3, except 
for global qols range 
of 6. 
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STATISTICAL METHODS 
 
Study I 
Mean scores of the individual transformed scores were calculated and presented 
with 95% confidence intervals. A difference of at least 10 points between time 
points was examined with a statistical significance test. Though the results were not 
normally distributed, the non-parametric Mann-Whitney U test was used and the 
level of statistical significance used was 5% (α=0.05). Results of QLQ-C30 were 
compared to age-and-sex stratified values in the general population, and if a 
difference of at least 10 points was found, statistical significance was examined 
with a Students t-test. 
 
Study II 
A selection of outcomes was made based on previous literature6,129,131,146 so as to 
minimize the risk of results due to chance (Table 5). Reponses were dichotomised 
as described on page 47. Associations between preoperative patient and tumour 
characteristics and postoperative HRQL were examined using logistic regression 
models and presented in the form of odds ratios (ORs) with 95% confidence 
intervals (CIs). Adjustment was made in a basic model, including sex, age and 
tumour stage and moreover in a multivariable model, including BMI, comorbidity, 
complications, and type of operation.  
 
Study III 
Two hypotheses were advanced. Firstly, in changes of at least 10 points in the 
baseline score, associations between patients and survival were assessed. Secondly, 
a change of 10 points or more when subtracting the individual baseline score from 
the follow-up score was examined for association with survival. Cox proportional 
hazard models153 were used, and results were presented as Hazard ratio with 95% 
confidence intervals. Both hypotheses were adjusted for sex, age, performance 
status, cancer site, tumour stage and histology. The second hypothesis was also 
adjusted for treatment and baseline score of examined item (or scale). Due to the 
number of statistical tests, our criterion for statistical significance was p<0.01. The 
assumption of proportional hazards was evaluated and a test of unbiased estimation 
and accurate confidence interval coverage probabilities was carried out154. 
 
Study IV 
A selection of outcomes, based on previous literature127,134,135,144,146,147, so as to 
minimize the risk of results due to chance, was made (Table 5). Responses were 
dichotomised as described above (page 47). Associations between HRQL and 
survival were evaluated using Cox proportional hazard models and presented as 
Hazard ratios with 95% confidence intervals. Adjustments were made for sex, age, 
tumour stage, comorbidity, histology, operation type and postoperative 
complications within 30 days of surgery. A survival graph was drawn using the 
Kaplan-Meier method. 
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RESULTS 
 
STUDY PARTICIPANTS 
Table 6. Participation rate of patients in Studies I-IV.  
Table 7. Selected characteristics of the participants of Studies I-IV  
 I II III IV 
Number of patients (%) 
In original cohort 358 (100) 586 (100) 216 (100) 614 (100) 
Alive after:     
- six months 280 (78) 463 (79) 169 (78) 490 (80) 
- three years 117 (33) --- ---- --- 
Answered HRQL of alive:     
- at baseline -- -- 188 (87) -- 
- after six months 93 (79)* 355 (77) 132 (78) 401 (82) 
- after three years 87 (74)* -- -- -- 
* Only patients alive at three years (117) were eligible for the study, number and percentage is based on those. 
 I II III IV 
Number of patients (%) 
Male sex 62 (71) 287 (81) 91 (69) 326 (81) 
Mean age 66 66 64 66 
Comorbidities 
Yes, at least one 57 (66) 244 (69) N/A
 
274 (68) 
Tumour location 
Upper or middle 
Lower 
Cardia (Siewert II-III) 
Stomach 
12 (14)
39 (45)
36 (41)
--
57 (16)
139 (39)
158 (44)
---
N/A
N/A
N/A
38 (29)
 
64 (16) 
158 (39) 
179 (45) 
-- 
Tumour stage 
0-I  
II 
III 
IV 
Unknown 
34 (39)
36 (45)
13 (15)
3 (3)
1 (1)
75 (21)
115 (32)
146 (41)
19 (5)
--
15 (11)
22 (17)
82 (62)
13 (10)
--
 
84 (21) 
120 (30) 
162 (40) 
33 (8) 
2 (1) 
Histology 
Adenocarcinoma 
Squamous cell carcinoma 
68 (78)
19 (22)
269 (76)
87 (25)
104 (79)
28 (21)
 
303 (76) 
98 (24) 
Treatment 
Surgery 
Neoadjuvant and surgery 
Radical chemoradiotherapy 
Adjuvant therapy 
80 (92)
4 (5)
--
3 (3)
313 (88)
22 (6)
--
20 (6)
61 (46)
46 (35)
25 (19)
N/A
 
356 (89) 
24 (6) 
-- 
21 (5) 
Complications 
Yes, at least one 36 (41) 153 (43) N/A
 
183 (46) 
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STUDY I – LONG TERM HRQL 
Of the 358 patients who underwent potentially curative surgery, the 117 patients 
(33%) who were alive after three years were eligible for this study. Of these 117 
patients, 93 (79%) returned the six months’ questionnaire and 87 (74%) their three 
years’ questionnaire. Out of the 117 patients, 78 (67%) patients had returned both 
the six months’ questionnaire and the three years’ questionnaire. The missing 
questionnaires were mainly due to administrative errors (15% of the six months’ 
and 17% of the three years’ questionnaires). 
 
Comparisons over Time 
In general, there were no clinically relevant differences (≥10 in mean scores) in the 
total group of patients between the assessments after six months and after three 
years. There were differences corresponding to a mild clinical change (5-10 points) 
regarding less fatigue, appetite loss, diarrhoea and financial difficulties, and 
increased dysphagia, reflux and dryness of the mouth after three years, compared to 
six months. Separate analyses to discover the direction of changes among the 
majority of the patients revealed that most patients remained on the same level of 
HRQL (individual mean score change within 10 points), and the proportions of 
patients who improved or deteriorated were similar. The greatest proportion of 
patients improved in fatigue (47%), oesophageal pain (45%) and reflux (42%). The 
aspect on which most patients deteriorated was dysphagia (32%). 
 
Comparisons with the General Population 
When mean HRQL scores from the QLQ-C30 questionnaire were compared to an 
age and sex-matched random sample of the Swedish general population, the 
patients showed clinically relevant and statistically significant poorer HRQL. 
Aspects of role and social functions, fatigue, nausea and vomiting, loss of appetite 
and diarrhoea were particularly affected. Furthermore, female patients also reported 
a poorer global quality of life, physical and emotional function scores, compared to 
the matched female general population. 
Figure 4. Mean score six months and three years postoperative.  
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STUDY II – INFLUENCES ON HRQL 
Of 586 patients treated with intended curative oesophagectomy, 463 (79%) patients 
were alive six months postoperatively and thus eligible for the study. Of these, the 
355 (77%), who completed the questionnaire, remained for final analysis. Missing 
questionnaires were mainly due to administrative errors, such as delayed registration 
of the patients (14%). 
 
Patient Characteristics 
Regarding associations between patient characteristics and HRQL, no associations 
were seen for sex. Middle-aged patients had a decreased risk of poor emotional 
function (OR 0.53 95% CI 0.30-0.93) compared to the younger age group. A lower 
risk of having poor social function was found among patients with high BMI (OR 
0.77 95% CI 0.62-0.96). Patients with comorbidities had a statistically significant, 
almost doubled increase in risk of poor physical function (OR 1.87, 95% CI 1.13-
3.08), role function (OR 1.94, 95% CI 1.16-3.25), fatigue (OR 2.17, 95% CI 1.31-
3.60), and diarrhoea (OR 1.87, 95% CI 1.04-3.34) compared to those without 
comorbidities.  
 
Tumour Characteristics 
Patients with AC had a statistically significant decreased risk of poor global quality 
of life (OR 0.43, 95% CI 0.24-0.75), physical function (OR 0.36, 95% CI 0.20-
0.64), role function (OR 0.45, 95% CI 0.25-0.80), fatigue (OR 0.49, 95% CI 0.28-
0.88), pain (OR 0.41, 95% CI 0.22-0.74), dyspnoea (OR 0.42, 95% CI 0.23-0.78) 
and coughing (OR 0.46, 95% CI 0.25-0.86) compared to patients with SCC. 
Furthermore, an advanced tumour stage (III-IV) indicated a statistically significant 
increased risk of poor role function (OR 2.30, 95% CI 1.23-4.30), loss of appetite 
(OR 2.40, 95% CI 1.23-4.66) and eating difficulties (for stage II OR 2.26, 95% CI 
1.19-4.29 and for stage III-IV OR 1.80, 95% CI 1.00-3.23) compared to patients 
with tumour stage 0-I. Regarding the location of the tumour, a middle or upper 
location was statistically significantly associated with an increased risk of poor 
global quality of life (OR 2.61, 95% CI 1.28-5.32), physical function (OR 2.09, 
95% CI 1.05-4.16) as well as a higher risk of dyspnoea (OR 2.76, 95% CI 1.35-
5.61) and coughing (OR 3.88, 95% CI 1.80-8.34) compared to patients with 
tumours of the gastric cardia. 
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STUDY III – CHANGES IN HRQL AND SURVIVAL  
Of 216 selected patients, 169 completed curative treatment and were alive at the 
six months’ follow-up. Of these, 132 (78%) had two complete HRQL 
assessments. Missing questionnaires were mainly due to administrational failure 
at baseline (13%), while at the follow-up this was mainly due to the fact that the 
patient had died or did not complete the planned treatment (22%). 
 
Differences in Baseline Scores between Patients 
Patients reporting at least 10 points higher score on the baseline dyspnoea had an 
18% increase in the likelihood of death (HR 1.18 95% C.I. 1.05-1.33, p-value 
0.006). No associations were found for global quality of life, physical function, 
role function, emotional function, social function, cognitive function, fatigue, 
nausea, pain, dyspnoea, insomnia, loss of appetite, constipation, diarrhoea or 
financial impact. 
 
Changes in the Individual Score between Baseline and Follow-up 
Regarding the change within a patient between baseline and postoperative HRQL 
a better recovery of physical function was associated with a lower risk of death 
six months after treatment (HR 0.85, 95% C.I. 0.76-0.96, p-value 0.007). 
Likewise, a higher risk of death was found for patients with a 10 point increase in 
problems with pain (HR 1.20, 95% C.I. 1.09-1.33, p-value < 0.001) and fatigue 
(HR 1.16, 95% C.I. 1.04-1.30, p-value 0.009). There was no evidence of non-
proportional hazards in any of the models presented. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Survival graph for patients illustrating differences between patients with stable 
or reduced pain versus those with at least a 10 point deterioration.  
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STUDY IV – POSTOPERATIVE HRQL AND SURVIVAL 
Of the 614 patients who underwent potentially curative surgery for oesophageal or 
cardia cancer, 124 died before six months’ follow-up and of those, who were alive, 
89 (18%) had missing data mainly due to administrative errors such as delayed 
registration six months postoperatively. The remaining 401 (82%) patients 
responded to the six months’ HRQL assessment. Patients were followed up for at 
least five years. 
  
Nearly every third patient was categorised as having poor global quality of life. 
Cox proportional showed a 55% increased risk of death for these patients, 
compared to those having good global quality of life (HR 1.55, 95% CI 1.19-2.02, 
p <0.01). Almost half of the patients (48%) were categorised as having a poor 
physical function and these had a 56% increased risk of death (HR 1.56, 95% CI 
1.23-1.99, p <0.01) compared to patients having good physical function. Regarding 
social function, one third of the patients was classified as poor, and these patients 
had a 52% increased risk of mortality (HR 1.52, 95% CI 1.19-1.94, p <0.01). About 
half of the patients reported that they were symptomatic from fatigue and they had 
a 65% increased risk of mortality (HR 1.65, 95% CI 1.30-2.11, p <0.01). 
Approximately one third of the patients was categorised as being symptomatic 
from pain and dyspnoea with Cox proportional hazard ratios showing an increased 
mortality of 45% and 54% respectively (HR 1.45, 95% CI 1.22-1.87, p <0.01 and 
HR 1.54, 95% CI 1.19-2.01, p <0.01 respectively). One of the highest hazards of 
death was found among the third of patients classified as symptomatic from loss of 
appetite which showed an increased mortality of 69% (HR 1.69, 95% CI 1.32-2.14, 
p <0.01). Only 9% of the patients were categorised as having symptomatic 
dysphagia and they had a 69% increased risk of death (HR 1.69, 95%C.I. 1.13-
2.51, p 0.01). Symptomatic oesophageal pain was seen in 37% of the patients 
resulting in an increased mortality of 29% compared to those stating that they had 
no or minor symptoms (HR 1.29, 95% C.I. 1.02-1.65, p 0.04).  
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 Table 8. Summary table of the results from Studies I-IV. 
Outcome Findings 
Global quality of life scale Might be affected by tumour location and histology. 
Postoperative value predictive for survival. 
Functioning scales  
Physical function Might be affected by comorbidities, tumour location and histology. A 
lack of recovery and a poor postoperative score associated with risk of 
shorter survival. 
Role function Might be affected by comorbidities, tumour stage and histology. 
Emotional function Might be better among middle-aged. 
Cognitive function No findings. 
Social function 
 
Might be better among the overweight. 
Postoperative poor function associated with risk of shorter survival. 
General symptom scales 
Fatigue Might improve in the long term. 
Might be affected by comorbidities and tumour histology. 
Deterioration from baseline and a poor postoperative score is 
associated with risk of shorter survival. 
Nausea & vomiting No findings. 
Pain 
 
Deterioration from baseline as well as symptoms postoperatively 
associated with risk of shorter survival.  
Might be affected by comorbidities and tumour histology. 
General symptom items 
Dyspnoea A poor baseline score and symptoms postoperatively associated with 
risk of shorter survival.  
Might be affected by comorbidities, tumour location and histology. 
Insomnia No findings. 
Appetite loss Might improve in the long term. 
Might be affected by tumour stage. 
Postoperative symptoms associated with risk of shorter survival. 
Constipation No findings. 
Diarrhoea Might improve in the long term.  
Might be affected by comorbidities. 
Financial difficulties Might improve in the long term. 
Oesophageal-specific symptom scales 
Dysphagia Might deteriorate in the long term. 
Postoperative symptoms associated with risk of shorter survival. 
Eating difficulties Might be affected by tumour stage. 
Reflux Might deteriorate in the long term. 
Oesophageal pain Postoperative symptoms associated with risk of shorter survival. 
Oesophageal-specific items 
Trouble swallowing saliva No findings. 
Choking No findings. 
Dry mouth Might improve in the long term. 
Taste problems No findings. 
Coughing Might be affected by comorbidities, tumour location and histology. 
Speech difficulties No findings. 
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DISCUSSION 
 
Cohort Studies 
There are two main types of epidemiological studies; observational and 
experimental. Observational studies can be analytic or descriptive and designed as 
case-control studies, cohort studies, ecological studies or cross sectional studies. 
Experimental studies in clinical settings are often performed as randomized 
controlled trials, which have been proclaimed as “the gold standard” for scientific 
results155. The main aim of randomisation is to reduce errors but in clinical research 
it might be unethical or unfeasible to randomise patients, and other strategies must 
be used instead to combat errors. Meta-analyses have shown that overall results 
from several experimental and observational studies are usually almost 
identical155,156 and the design is therefore more of an issue for internal validity155-
157. All four studies within this thesis are observational since it would have been 
impractical or impossible to randomise patients based on the studied exposures. 
The study design used in all four studies was cohort studies. A cohort study could 
be defined as a study in which a group of people with defined exposure is followed, 
so as to determine the incidence of an outcome, e.g. mortality or HRQL. The cohort 
might be compared to a group without the exposure, to determine the influence of 
the exposure158. The main advantage with cohort studies is that the researchers are 
able to collect data on the exposure before the outcome has occurred. 
Disadvantages include difficulties in tracing patients (lost to follow-up) and thereby 
missing data. Furthermore, observational studies could be either prospective, if the 
study was initiated before the outcome has occurred, or retrospective, if the 
outcome has already occurred when the study is initiated. All four studies within 
the thesis are considered prospective cohort studies since the outcome’s mortality 
and HRQL were unknown at the point in time of the inclusion of new patients.    
 
Validity  
The result of an epidemiological study is an estimate, which might be influenced by 
random or systematic errors. An estimate free of systematic errors is said to be 
perfectly valid158. The validity of a study is often divided into internal and external 
validity. Internal validity defines how well the study effects have been measured, or 
the lack of bias158. External validity defines how well the study results could be 
applied on people outside the studied population, i.e. generalisability158. Good 
internal validity is a prerequisite for external validity. Systematic errors are often 
named bias, and refer to any systematic error that results in incorrect estimate of the 
associations between exposure and risk of disease158,159. Bias may result in the over 
or underestimating of results, thereby reducing the internal validity159. Bias could 
be reduced by the study design, not the sample size. There are over 70 types of 
bias, classified within three main groups; selection bias, information bias and 
confounding159.   
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Selection Bias 
Selection bias means that differences exist in the exposures between participants 
and non-participants, resulting in the study population not representing the target 
population. Whether these differences exist or not is usually unknown, and 
selection bias is therefore suspected rather than observed158.  
Surgical research often has selection bias by assorting patients depending on, for 
example, age before an oesophagectomy is performed by a specialised doctor at a 
specialised hospital. The literature on oesophageal cancer is often based on single-
centres with different possible routines in the referral and acceptance of patients, 
resulting in selection bias and difficulties in comparisons between studies.   
A major reason for selection bias is loss of follow-up or missing data158. In Studies 
I, II and IV data from the population-based and nationwide SECC-registry were 
used. To be able to label a study population-based, the coverage of cases in a 
defined geographic region has to be as complete as possible. The coverage in the 
SECC-registry was 90% of the operated patients in Sweden, which is good. Non- 
participation was due to the diminished participation of five centres. Even if 
Studies I, II and IV used the same database of a total of 616 patients, the sample 
size analysed in each study differs. In Study I the three year follow-up had not 
passed for all patients. In Study II we excluded patients who had a curative surgery 
but non-radical pathological specimen, since they were concluded to have a 
palliative surgery and recurrences would confound the results. In Study IV we 
excluded two patients with palliative operations, but kept all other patients in the 
SECC-registry since we wanted to analyse association between HRQL and 
survival.  
Regarding the missing six months’ HRQL in Studies I, II and IV the risk of 
selection bias should be negligible, since it was mainly due to slow initial 
administration, not the patient’s own choice.  
In Study III, a single centre cohort was used, selection bias could exist between 
patients treated at the included hospitals who were thereby given possibilities of 
participating in the study versus patients treated at other hospitals and thereby 
excluded from possibilities of participating in the registry. Among patients included 
in the study, the participation rate baseline HRQL assessment was high (87%), 
reducing the risk of selection bias. 
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Information Bias 
Information bias, also called misclassification, means errors in the measuring of the 
outcome or exposure. It can be differential if it differs between subjects with or 
without exposure or outcome, or non-differential if missing data is unrelated to the 
exposure and outcome. Differential misclassification may cause unpredictable 
distortion of the risk estimate, while non-differential misclassification should rather 
dilute any effect158. 
 
Data Collection 
In Studies I, II and IV the SECC-registry was used. The registry should have a low 
risk of information bias due to the fact that only a handful of clinicians and 
researchers, working outside the participating hospitals, extracted data, as opposed 
to all participating clinicians at their hospitals making their own interpretation as to 
what and how to report data.  
Furthermore, the exposure and outcome were noted, based a strict and predefined 
protocol without prior knowledge of future studies´ exact combinations of 
exposure, such as curative surgery or the outcomes HRQL or mortality. Therefore 
any misclassification should be non-differential, which is possible even if the 
protocol’s definition was followed stringently. For example, even if the 
complication myocardial infarction was clearly defined, it is possible that the 
documentation in the medical records differs between doctors and centres. Also, 
the outcome myocardial infarction was assessed binarily (yes or no), but in the 
clinic a myocardial infarction could range from a new Q-wave on the ECG to a 
severe clinical condition. Likewise, in Study II our grouping of comorbidities 
might have been too rough.  
In Study III a core staff followed a predefined study protocol before any treatment 
or outcome was known. Since the data is collected from a single centre, the risk of 
differences in documentation between patients should be small, and the risk of 
misclassification could thereby be even smaller than in the SECC-registry. 
Regarding HRQL outcomes in all four studies, the self-completing of 
questionnaires without insight from a care provider at the local hospital might have 
reduced the risk of information bias (e.g. observer expectation bias). On the other 
hand, there might be some element of selective reporting100 present, meaning that 
patients want to contribute correctly by reporting symptoms they think researchers 
might find interesting. In Study III, baseline (before start of treatment) assessment 
was used. However, the baseline assessment might have been affected by the 
awareness of the cancer diagnosis, symptoms from it, or upcoming major surgery, 
which might cause non-differential misclassification. Unfortunately, the time point 
for baseline differed between patients in different treatment strategies. Furthermore, 
a handful of patients filled in their baseline after the start of chemotherapy but 
before the likelihood of developing side effects, and their baseline might have 
caused a differential misclassification. 
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HRQL Instruments 
To reduce information bias, validated questionnaires were used to assess HRQL in 
all four studies. However, further improvement can be achieved. Since all tests 
assume a lack of errors, the cut-off of Cronbach’s alpha= 0.7 is acceptable, but a 
value of 0.8-0.9 would have been a more desirable level for good reliability67. 
During the validation of QLQ-OES18 as many as 42% of the scales had a lower 
alpha than the predefined cut-off (0.7); it was stated as a weakness but the 
questionnaire was not further revised104. The number of patients in the validation 
was also a bit too low to allow watertight stratified validation104.  
Within the questionnaires there is a risk of information bias. A patient can easily 
fill in wrong answer by mistake, thereby causing a random error, especially when 
the scale is reversed after the initial questions on QLQ-OES18. Such 
misclassification should be non-differential, and it was not highlighted as a 
problem during testing104. 
 
 
Confounding 
Confounding is derived from the Latin word confundere meaning to mix together 
and serves for the “confusion of effects”. A confounder is an external factor 
interfering with both the exposure and outcome, but not acting in the causal 
pathway.  
There are no statistical models to discriminate between a confounder and a variable 
intermediary in the causal pathway. Instead, control of confounders can include 
restricting the study design and the use of statistical analyses allowing adjustments 
based on previous literature and clinical knowledge159.  
In Studies II, III and IV adjustments were discussed with experienced oesophageal 
cancer surgeons, and statistical methods were discussed with statisticians. In 
Studies II and IV we unfortunately lacked some potentially important confounders, 
such as baseline HRQL, performance status, tobacco smoking, alcohol intake and 
weight loss. Even if the histological type SCC is closely connected to alcohol 
intake and tobacco smoking, and adjustments can thereby be indirectly made for 
these variables, it would have been even more valuable if the direct data had been 
available for adjustments. However, self-reported alcohol intake and smoking 
habits are difficult to assess reliably and blood sample tests only reveal recent 
use160,161. Study III provided both baseline HRQL and performance status, but 
lacked data about comorbidities and complications.  
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Precision and Random Errors  
Precision concerns how close to bull’s eye the dart arrow has landed. It is 
influenced by random errors (chance) and can be tested with the size of confidence 
intervals and p-values. A common confidence interval is 95%, meaning that in 95 
of 100 similar studies the mean score of the studies will be within the confidence 
interval. P-values measure whether the null hypothesis (that no relation between 
exposure and outcome exists) is true or not. The p-value also answers the 
probability of observing an association at least as strong as the actual observation. 
In medical research, the p-value is often used as a dichotomy (yes or no) for 
decision making, meaning that the predefined level of p (often 0.05) determines 
whether a study has a significant result or not. This approach could be criticised, 
since there are many other aspects of a study that need to be taken into account. 
Nevertheless, there is a need to define a level of p in advance.  
 
Type I Errors 
Type I errors occur when the null hypothesis is rejected despite being true (“false 
positive”). Therefore, unexpected findings when many tests are performed 
simultaneously could be due to the type I error multiple testing or a true result. 
Type I errors could be reduced by larger sample size and fewer tests. In order to 
reduce risk of multiple testing, in Studies II and IV we performed a selection of 
outcomes that we deemed to be of highest relevance rather than testing all HRQL 
outcomes. Still, in Study II a drawback of exploring several HRQL outcomes 
simultaneously might have emerged. In Study III we a priori decided not to adjust 
for multiple testing, but instead used a difference of at least 10 points between 
assessments before analysing p-values.  
 
Type II Errors 
Type II errors occur when the null hypothesis is not rejected despite being false 
(“false negative”) or plainly speaking “an absence of effect is not proof of lack of 
effect”. Type II errors are reduced by an increased sample size. The lack of effects 
in Study I could have been due to a small sample size, but the power calculations 
were satisfying, so other explanations might be more likely. 
In Study III gastric cancer patients were included to increase the statistical power. 
Since gastric cancer patients are similar regarding risk factors, symptoms, treatment 
and HRQL outcomes, we found it reasonable to increase power by including them. 
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HRQL MEASUREMENTS 
Choice of Instrument 
Philosophers have forwarded criticism that quality of life in medical research often 
assesses outcomes in order to measure effectiveness of treatment64. It has been 
highlighted as a problem to lump together disparate issues such as physical 
symptoms (pain, fatigue) and emotional states (how happy or depressed), with 
social and occupational functioning in one single category, thus measuring 
instrumental onsets (what´s good for us as means for other purposes, e.g. working 
for money) and final values (what’s finally good for us in life, e.g. happiness) at 
one time64. The QLQ-C30 mainly focuses on physical functioning and clinical 
symptoms, while cognitive and emotional aspects are covered in less detail 162. To 
achieve a better understanding of changes in HRQL, a disease-specific instrument 
could be supplemented with a generic, an aspect or a study-specific questionnaire 
measuring the meaning of illness, fears and hopes86 163-167. So, even if the 
questionnaires used are perfect, we could have missed aspects of importance to 
patients, thereby affecting the internal validity.  
 
Scoring of the Questionnaires  
Transformation of Scores 
The EORTC questionnaires generate categorical ordinal data from ordered 
response alternatives with descriptive labels such as “Not at all” and “Very much”. 
In Studies I and III the scoring was made according to the scoring manual105, 
meaning linear transformation to a score between 0-100. By doing this, single items 
retain their origin form as categorical data, meaning that there is an order between 
values, although distances between them are meaningless and unknown. The 
transformed individual score for single items can only be 0 points, 33 points, 67 
points or 100 points. These ordinal values are by nature only comparable to a 
limited extent, meaning e.g. that if patient A has 67 points and patient B has 67 
points they have the same HRQL, but if patient C has 33 points we know it is lower 
but it is impossible to know the difference, since simple subtraction (67-33 =34) 
can not be done in a non-linear relation. Therefore, and due to the fact that single 
items can only take a limited amount of outcomes, the subtraction of the individual 
scores in order to find a 10 point change or not in Study III can be questioned; 
instead we could just have looked for deterioration or improvement as a binary 
outcome on single items. Regarding multi-item scales, the patient’s result could 
end up in up in several different categories, and it might then be more relevant to 
use a predefined cut-off even in individuals. But the problems with multi-item 
scales are that it is assumed that equal weight shall be given to all questions within 
a scale, every score is worth the same and the distance between every response 
alternative is equal. Both subjective weighting of items within a function and a 
more sophisticated scaling such as the VAS-scale, a simple line from 0 “no pain” to 
10 “worst possible pain” would be interesting105. To circumvent the issue of 
categorical data, response alternatives have numbers (1,2,3,4) and the text “Very 
much” could be seen as merely informative.  
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Dichotomizing of Raw Scores 
The scoring method of dichotomizing, used in Studies II and IV, was chosen to be 
able to perform logistic regression and adjust for confounders. The cut-off based on 
raw answers was chosen so as to be independent of distribution of answers and to 
be clinically understandable. The same cut-off was used for all questions and 
therefore one single answer of “Quite a bit” or “Very much” qualified the patient to 
poor HRQL. This approach dilutes rather than concentrates our results. However, 
the worst scenario is for physical function, which has five questions, if a patient 
answers “Not at all” to four of them and “Quite a bit” to one, it produces the fairly 
good score 87, but with our dichotomising the patients was assessed as “Poor 
function”. However, retrospectively, this does not seem to be a big issue since only 
around 1% of the patients, classified as having “Poor physical function”, scored as 
high as 87. To avoid fishing, we did not explore alternative cut-offs, even if others 
were possible, e.g. the mean score of the total group. This cut-off would be based 
on the actual study sample, but could be hampered by a skewed distribution, a 
small study sample and outliers. Furthermore, the mean score could be misleading 
in single items. To exemplify, in Study IV our mean scores for the single-item 
diarrhoea was 32 points. The distribution among the four possible individual 
outcomes was 0 points: 38%, 33 points: 36%, 67 points: 18% and 100 points: 8%. 
If the same categories as in Studies II and IV are used, (“No or minor symptoms” 
and “Symptomatic”) all of 62% would be “Symptomatic” even if 74% report 
problems with diarrhoea bothering them as “Not at all” or “A little”. A third 
possible cut-off is the median score. It is not dependent on sample size or sensitive 
for outliers but automatically classifies half of the patients as poor and half as good, 
irrespective of how they have answered, and finally, the patients with the median 
score play a crucial role irrespective of which category they are included in.  
 
Clinical Interpretation 
Mean Scores, Clinical Significance 
The consideration of the clinical relevance and usefulness of a study is of great 
importance, albeit a complex matter. First of all, even if HRQL assessments are 
common in clinical trials it is still possible, or rather likely, that clinicians do not 
have a sensitive understanding of, for example, a mean score of 70 points (out of 
100) for physical function among cancer patients. To improve this, reporting of 
additional raw scores might be helpful105. Secondly, as discussed above, mean 
scores are complex to interpret and compare. Thirdly, nothing is known as to 
whether an improvement of 10 points in the mean score for a group of patients is of 
equal importance over the entire scale, such as changing from 20 points to 30 
points versus from 80 points to 90 points. Fourthly, even if the 10 point cut-off for 
clinical relevance is widely used, only two studies have examined this cut-off and 
none in oesophageal cancer patients. Furthermore, improvement seems to be 
noticed earlier than deterioration110, therefore it has been suggested that different 
cut-offs could be used for improvement (5 points) and deterioration (10 points). 
Also using a cut-off of 10 points in the mean score change ignores the distribution 
of results. In Study I we only found a weak mean score deterioration (5 points) 
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regarding reflux, even though the greatest portion (42%) reported increased reflux 
of at least 10 points. The explanation for the “lack” of associations might be that 
the patients, who had improved, generally had greater changes or existence outliers. 
The supplementary table, stating the proportion of patients with improvement 
/stable /deteriorated HRQL, might help the reader to understand changes better. 
The table also reinforces the conclusion that the majority of patients are likely to 
have a stable postoperative HRQL regarding most outcomes. An additive clinical 
method for judging numbers presented by the computer is to look at results on 
correlating scales. In Study III, the findings of association between survival on the 
correlating physical function and fatigue should minimize risk of random findings. 
Another clinically recognised method is to decide treatment effect by numbers 
needed to treat (NNT). It can be calculated when a trial has a binary outcome, such 
as the portion of patients having good or poor quality of life67. It is uncommon in 
HRQL research, probably because clinical trials evaluating treatment rarely have 
HRQL measured binarily as a primary outcome. Still, if for example, two 
interventions for dysphagia are compared and evaluated with HRQL, instead of 
presenting mean scores and concluding that a clinically relevant difference between 
groups exists, one could calculate the number of patients needed to treat for one 
patient to gain a 10-point benefit.  
 
Response Shift 
Response shift is most likely to be present when measurements are made before 
and after major treatment83. As patients start to recover from major cancer surgery, 
such as oesophagectomy, it is possible that they cope with the disease and report 
better HRQL than expected168. In Study III, where measurements were made before 
and after treatment, the presence of response shift might have diluted our results. 
However, detecting response shift is difficult, and it was described by Fayers and 
Hays as a dolphin swimming in the ocean and every now and then emerging to 
breathe; everyone (every researcher) knows it is there and can witness when it 
emerges from the water, but when and where it is going to surface exceeds our 
current understanding169. Study I also included repeated measurements, and our 
findings of a constantly low HRQL might even be a deteriorated HRQL. 
 
Timing 
The time point of six months to assess HRQL in all four studies was carefully 
chosen, based on previous literature and an attempt to slip between confounding of 
recovery and influence by tumour recurrence6,11,60,124,130-132,140,141. A benefit from 
choosing a later time point is that the disease-free patients are more likely to have 
recovered to a large extent and patients with recurrences are more likely to have 
developed measurable changes in HRQL. But since it is clinical research, choosing 
an earlier time point might lead to earlier awareness and thereby be of greatest 
importance.  
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FINDINGS AND EXPLANATIONS 
 
STUDY I – LONG TERM HRQL  
The long term (three years) HRQL seems to be comparable to levels measured six 
months postoperatively, and generally worse than the general population. Certain 
aspects seem to be more commonly improved, such as fatigue and pain, while 
reflux and dysphagia seem to increase in the majority of patients. The sums of the 
weaknesses discussed above are the use of 10 points as cut-off both for 
improvement and deterioration and a possible small sample. Previous literature 
supports some of the findings in the study6,124,126,129,132. Fatigue has been seen to 
improve in the long term, which is in line with our findings, but still the level of 
fatigue is higher than that in the general population. In contrast, dysphagia has also 
decreased in previous studies6,128, although our patients reported an increase. Some 
biological mechanisms are likely to explain the findings. The improvement in 
fatigue and pain might reflect that patients have not recovered fully six months 
after surgery. Dysphagia is likely to be due to a local recurrence or a postoperative 
stricture, but since all patients were alive three years postoperatively, and 
recurrences are known to come quickly, a possible explanation is strictures. The 
deteriorated reflux is a common effect of the operation. 
 
STUDY II – INFLUENCES ON HRQL  
The main finding was associations between tumour characteristics and poor HRQL, 
but rarely with patient characteristics, including age, sex and BMI, except for 
comorbidities, which negatively affected HRQL. Methodological issues were 
discussed above, and one issue is that our dichotomizing might not be optimal. 
Likewise our grouping of for example comorbidities might have been too rough. 
There are no previous studies with a main aim to evaluate differences between 
patients´ characteristics and tumour characteristics among oesophageal cancer 
patients. Some explanations are likely for the findings. The lack of differences 
between sexes and age groups might suggest that HRQL in cancer patients mainly 
depends on their disease. Furthermore, ongoing projects, such as the GENEQOL 
might reveal interesting information81. The findings of associations between 
comorbidities and poorer HRQL should not surprise any clinician, since all 
diseases have symptoms, and patients with additional diseases should be more 
likely to suffer from poorer health. The associations between a more advanced 
tumour stage and poorer HRQL might reflect a more extensive operation, 
complications and poorer prognosis. Information about alcohol intake and smoking 
habits might explain both the differences between histological types and different 
locations, since a higher tumour is more likely to be a SCC than an AC. 
  62 
STUDY III – CHANGES IN HRQL AND SURVIVAL  
The main finding of the study was an increased risk of mortality among patients 
with more problems with dyspnoea at baseline and among patients who did not 
recover physical function six months after surgery. There was also an increased 
mortality risk in patients reporting lack of recovery from fatigue or pain after six 
months.  
The major weaknesses are that the cohort is based on a single centre with a possible 
source of selection bias, a relatively small sample, gastric patients were also 
included, and the time point for baseline.  
A previous study has found baseline dyspnoea as prognostic for major morbidity 
after oesophagectomy134. Since only few studies have investigated changes in 
HRQL and none in oesophageal cancer patients, the results were compared to other 
cancer patients. Interestingly, pain has been found associated with survival in both 
prostate cancer patients and head and neck cancer patients, as well fatigue has been 
found associated with survival in patients with prostate cancer146,170.  Findings of an 
association with survival for changes between baseline and follow-up suggest that 
HRQL aspects mirror the natural course of disease with quick lethal recurrences. 
The associations between baseline dyspnoea could both be a random finding and a 
true finding, reflecting an influence of factors that might affect prognosis such as 
comorbidities or the general health condition. 
 
 
STUDY IV – POSTOPERATIVE HRQL AND SURVIVAL  
The main findings of Study IV were the associations found between poor HRQL 
six months after surgery and the risk of mortality. The risk ranged from a 29% 
increase for patients with oesophageal pain to 69% for patients with loss of appetite 
and dysphagia.  
The weaknesses discussed above are mainly the dichotomizing of HRQL based on 
raw answers and the time point of six months. 
There is only one previous similar study147 which investigated three month 
postoperative HRQL in relation to survival. Our findings are in line with that study, 
in that the previous study found social function and pain to be prognostic. The 
findings in this study of more HRQL items being prognostic, compared to what 
was found in their study, could be explained by the fact that patients after three 
months are still recovering from surgery to a larger extent than they are after six 
months. 
A biological mechanism explaining the findings is a higher level of tumour 
recurrences in the group with poorer HRQL.  
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CONCLUSIONS 
 
Some conclusions can be drawn from the four studies included in the thesis, 
namely: 
 
• Patients who undergo curative surgery for oesophageal cancer are unlikely 
to recover in most aspects of HRQL within three years. 
 
• A more advanced oesophageal tumour stage negatively affects postoperative 
role function, loss of appetite and eating difficulties. 
 
• A lower location of the oesophageal tumour might come with better 
postoperative global quality of life and physical function, as well as less 
dyspnoea and coughing. 
 
• Patients with oesophageal adenocarcinoma might have better postoperative 
global quality of life, physical function, role function as well as less fatigue, 
pain, dyspnoea and coughing, compared to patients with oesophageal 
squamous cell carcinoma. 
 
• Comorbidity among oesophageal cancer patients negatively affects 
postoperative physical function, role function, fatigue and diarrhoea. 
 
• Age, sex and BMI do not affect postoperative HRQL in oesophageal cancer 
patients. 
 
• Baseline dyspnoea could be prognostic for survival in groups of 
oesophageal cancer patients undergoing curatively-intended treatment. 
 
• Oesophageal cancer patients without lack of recovery of physical function 
or persistent problems with fatigue and pain after curatively-intended 
treatment could be running an increased risk of mortality.  
 
• Oesophageal cancer patients with a poor postoperative global quality of life, 
physical function, social function, or patients being symptomatic from 
fatigue, dyspnoea, loss of appetite, dysphagia or oesophageal pain run a 
higher risk of mortality.  
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IMPLEMENTATIONS 
 
A researcher needs to process and interpret results so as to provide clinically useful 
information, otherwise there is a risk of research becoming merely an academic 
exercise171. Our main aim, to clarify association between postoperative HRQL and 
survival, has been achieved and our main findings were in line with our hypothesis. 
If this has been the invitation to break down our aims and speculated benefits of the 
results to a clinically useful level, then the patients themselves have been the 
motivators. Oesophageal cancer patients´ and their relatives’ experience of a 
patient’s step from being healthy to being close to death are very rapid5,172. It also 
seems to happen without warning although the delay in diagnosing is partly due to 
unawareness of severity in symptoms4. There is therefore a huge need of 
information about the expected outcome of the operation and recovery time173. The 
results of the four studies are interpreted below in relation to our three aims 
regarding how HRQL could be implemented in the clinical prognostic jigsaw. 
 
Clinical Warning Signs and Prognosis. 
When meeting a patient, a doctor can, with support from Studies III and IV, use 
poor or deteriorated HRQL measures as a reason to bring up a discussion of a 
possible poor prognosis. Certain aspects such as generally poor HRQL, failure to 
recover physical function, increased pain or fatigue, deserve attention. Our findings 
are not likely to improve the individual prognosis but possibly the accuracy of it. 
 
Further Knowledge for Improvement of Follow-ups 
The most common initial oesophageal cancer symptom is dysphagia. The findings 
of recurrent dysphagia in a major part of the long term survivors in Study I, in 
conjunction with the lack of relevance in changes of it in Study III, support the 
claim that dysphagia is more likely to be due to stricture than to recurrence. Still, 
dysphagia could be a sign of a recurrence, a few patients in Study IV had severe 
dysphagia, and the hazards ratio of mortality in that group of patients was among 
the highest. Therefore, dysphagia needs to be followed up. Symptoms such as 
fatigue, and difficulties in handling daily activities due to physical limits should 
prompt clinical attention according to Studies III and IV. Study II improves the 
knowledge of the effect of  
comorbidities on HRQL, which points to the need for physicians to work 
multidisciplinarily, with the aim of optimizing for example the lung or heart 
function. Likewise, if comorbidities are not present in a patient with poor HRQL, 
Study IV indicates that doctors should actively seek for recurrence or other 
explanations, instead of accepting the presence of severe fatigue in older patients. 
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To Facilitate Basic Data for Informed Consent Treatment  
Even if the aim of surgical operations for oesophageal cancer is to cure, 
information on side effects and their duration is important. Study I verifies that side 
effects remain for a long period of time, while Studies III and IV suggest that 
deterioration in certain HRQL aspects should raise the issue of limitation in 
treatment. Study II reminds us of relativity in age, a healthy 80- year-old might 
tolerate surgery better than an otherwise poorly 60-year-old.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cartoon reproduced with kind permission of growing old disgracefully. 
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FUTURE RESEARCH  
 
There are several possible issues for future research in the area of this thesis. Some 
methodological issues have been sparsely explored and deserve attention, such as 
how to present HRQL, especially in other ways than as mean scores. Alternatives 
for dichotomizing the responses need to be further explored, as well as alternative 
methods for scoring; presentation including weighting of questions and alternative 
response alternatives would be interesting.  
It would also be interesting to study which outcomes should be analysed at what 
time point, so as to avoid multiple tests and random findings. Likewise, it would be 
interesting to find out how differences in generic instruments such as SEIQoL, or 
comorbidities such as depression, could explain variations in individual baseline 
HRQL, as well as the longer term outcome.   
Closely related to methodological issues, it is important to study how HRQL could 
be implemented in daily clinical care. Today, clinicians usually appreciate the 
importance of HRQL outcomes, but not how to use them171. Research addressing 
clinical implementations should have priority.  
Another interesting and sensitive topic is to search for biological explanations for 
subjective symptoms such as tumour recurrence. This type of studies would 
possibly address the problems with lack of clinical use, since results might easily 
be understood by clinicians. Other interesting biological mechanisms are the 
individual comorbidities, or rather their self-rated severity of the disease. In 
patients with SCC in the larynx, pre-treatment levels of haemoglobin have been 
found to be prognostic174 and likewise, potential influence of levels of haemoglobin 
and inflammatory markers, including tumour factors and CRP, would be interesting 
to evaluate among oesophageal cancer patients127.  
The often claimed reason for association between HRQL and mortality is tumour 
recurrences, but this remains to be proven.  
  
 
 
 
 
 
 
  68 
    69 
POPULÄRVETENSKAPLIG 
SAMMANFATTNING 
 
BAKGRUND 
Cancer i matstrupen, esofagus, utgör i Sverige endast 1% av alla cancerfall, vilket 
motsvarar ca 400 nya fall per år. Cancern är vanligare globalt sett och av någon 
okänd andledning ökar den i Europa och Sverige. Eftersom matstrupen ligger djupt 
skyddad innanför bröstkorgen och är eftergivlig i sin natur kan cancern utvecklas 
ganska ostört utan upptäckt.  
Sväljningssvårigheter och viktnedgång är de vanligaste symptomen. När en patient 
väl får sin diagnos har tumören ofta vuxit sig stor lokalt och även spridit sig som 
fjärrmetastaser (dottertumörer).  
Den etablerade behandlingen med botande syfte är kirurgi. Operationen är 
omfattande och påfrestande för patienten och den efterföljs ofta av allvarliga 
komplikationer, varför patienten som opereras bör vara i god fysisk form. Tyvärr är 
det bara cirka en fjärdedel av patienterna som både är i fysisk form och har en 
tumör som är i ett så pass tidigt stadium att den kan opereras bort. För övriga 
patienter är prognosen mycket dålig med en förväntad överlevnad på ett år. Trots 
lyckad operation är det bara cirka 30% som överlever fem år (svenska data). Ett år 
efter operation har ungefär en tredjedel fått återfall, och deras förväntade 
överlevnad är då endast några månader. 
Hälsorelaterad livskvalitet saknar en tydlig gemensam definition men de flesta är 
överens om att det är multidimensionellt och omfattar fysiska, emotionella och 
sociala aspekter av hälsa utifrån patientens perspektiv. Livskvalitet mäts ofta 
genom att en patient besvarar en enkät med frågor om symptom och funktioner. 
Hos cancerpatienter finns flera biologiska förklaringar för påverkan på 
livskvaliteten. Dels påverkar cancern patientens upplevda trötthet och smärta och 
dels påverkar kirurgisk behandling patientens svälj- och magtarmfunktion, med till 
exempel halsbränna och diarre som följd.  
Tidigare studier har visat att patienter som opereras för matstrupscancer behöver 
minst sex till tolv månader på sig för återhämtning avseende livskvaliteten, men 
väldigt lite är känt om den långsiktiga livskvaliteten. Likaså är det okänt huruvida 
livskvaliteten efter operation, eller förändringar i livskvalitetsmått under perioden 
före till efter operation, är kopplade till överlevnad. 
 
METODER 
Avhandlingen omfattar fyra delarbeten. Delarbete I, II och IV är baserade på ett 
svenskt kirurgiskt forskningsregister för matstrupscancer (SECC-registret),  
omfattande totalt 616 patienter. Detta motsvarar ca 90% av alla patienter som 
opererades i Sverige under perioden 2001 till 2005. 
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Delarbete III är baserat på en databas byggd på patienter från ett centra i Bristol, 
England, där hitills 260 matstrupscancerpatienter har inkluderats. I samtliga arbeten 
har livskvalitet mätts med enkäter utvecklade av ett europeiskt nätverk för 
forskning och cancerbehandling, European Organisation for Research and 
Treatment of Cancer (EORTC). EORTCs har en enkät för generella 
cancersymptom (QLQ-C30) samt en specifik enkät för matstrupscancersymptom 
(QLQ-OES18). Ett exempel på en av de fem frågorna som ingår i begreppet ”fysisk 
funktion” är –”Har du haft problem med att ta en kort promenad under den senaste 
veckan?” Svarsalternativen är: ”Inte alls”, ”Lite”, ”En hel del” samt ”Mycket”. När 
patienten svarat på samtliga frågor i enkäten omvandlas svaren enligt en manual till 
ett värde mellan 0 och 100, där ett högt värde för funktioner innebär att patienten 
har bra funktion medan ett högt värde för symptom betyder att patienten har 
mycket problem med symptom.  
 
I delarbete I jämfördes livskvaliteten sex månader efter operation med 
livskvaliteten tre år efter operation. Medelvärdet för hela gruppen räknandes vid 
bägge tillfällena. Om minst en 10 poängs skillnad (skala 0-100) mellan 
tidpunkterna hittades, tolkades det som kliniskt intressant. 
I delarbete II undersöktes eventuella samband mellan livskvalitet och olika 
patientrelaterade faktorer såsom kön, ålder, andra sjukdomar och övervikt samt 
cancerrelaterade faktorer såsom tumörstadium, tumörens läge i matstrupen och 
tumörens vävnadstyp. För att kunna justera för störfaktorer, samt räkna ut en 
skillnad i risk för bra eller dålig livskvalitet med relativa risker, grupperades 
patienternas svar i ”bra” eller ”dålig” funktion respektive om betydande symptom 
förelåg eller inte.  
I delarbete III utvärderades en eventuell koppling mellan överlevnad och 
skillnader i livskvaliet före och efter behandling med botande syfte. En skillnad på 
10 poäng (skala 0-100) mellan värdet före och efter behandlingen klassades som 
kliniskt intressant. Samband mellan kliniskt intressanta skillnader och överlevnad 
testades i särskilda statistiska analyser.  
I delarbete IV utvärderades det om skillnader i livskvalitet efter operation var 
kopplat till överlevnad. Relativa risker räknades och samma gruppering som i 
delarbete II användes. 
 
RESULTAT 
Delarbete I 
Inga kliniskt relevanta skillnader i hälsorelaterad livskvalitet kunde påvisas mellan 
sex månader och tre år efter operation. Det fanns dock en tendens till minskad 
trötthet, aptitförlust och diarré samt försämrad sväljförmåga i den senare 
utvärderingen. Jämfört med Sveriges befolkning hade patienterna sämre social 
funktion och mer trötthet, illamående och diarré. Tabeller över andelen patienter 
som hade förbättrats, varit stabila respektive försämrats mellan mätpunkterna 
visade att majoriteten av patienterna varit stabila i sin livskvalitet.  
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Delarbete II 
Patientrelaterade faktorer såsom kön, ålder och övervikt inverkade inte nämnvärt 
på livskvaliteten medan samtidig förekomst av andra sjukdomar påverkade den 
negativt. Bland de cancerrelaterade faktorerna visade sig vävnadstypen och 
tumörstadiet vara kopplat till livskvaliten efter operation. 
 
Delarbete III 
Patienternas självupplevda andningsbesvär före den i botande syfte genomgågna 
behandlingen visade sig vara kopplat till överlevnaden. Även skillnader mellan 
livskvalitet före och efter operation var kopplat till överlevnad. Patienter som inte 
återfick sin fysiska funktion eller som rapporterade en ökad trötthet eller smärta 
hade sämre chans till  överlevnad.  
 
Delarbete IV 
Patienternas livskvalitet sex månder efter operation visade sig vara kopplad till 
chansen för överlevnad. Om patienten hade klassats ha dålig fysisk funktion 
befanns en 56% ökad risk för död jämfört med personer som hade god fysisk 
funktion. 
 
DISKUSSION 
Delarbete I 
Medelvärdet för hela grupper kan vara missvisade på grund av att få patienter med 
mycket avvikande värden får stort inflytande. Likaså kan hälften ha förbättras och 
andra hälften förämrats lika mycket, med resultatet att medelvärdet förblir 
oförändrat. Även gränsen 10 poäng kan ha varit suboptimal då tidigare 
metodologiska studier har visat att förbättringar kan märkas tidigare än 
försämringar.  
 
Delarbete II och IV 
I analyserna användes en metod för att klassa patientens livskvalitet som ”bra” eller 
”dålig”, vilket kan ha medfört viss felklassifikation. Troligast har sådan 
felklassifikation spätt effekter snarare än att den kan förklara positiva samband. 
Tidpunkten sex månader efter operation bedömdes som optimal i glappet mellan 
påverkan från ofullständig återhämtning av sin livskvalitet och påverkan från 
återfall i cancern. 
 
Delarbete III 
Vid upprepade mätningar kan värdena påverkas av att en patient ändrat uppfattning 
om svårighetsgraden av exempelvis smärta, d.v.s. den smärta som patienten nu 
klassar som svår är ingenting mot vad den var innan operation. Detta medför att 
patienten inte klassar sin smärta lika högt på skalan, d.v.s. denne svarar  ”Lite” 
istället för ”En hel del”. Om detta har skett kan vi inte svara på, men om det gjort 
det har det sannolikt spätt ut resultatet. Vidare kan det ha funnits bättre alternativ 
till den gräns vi använt som kliniskt relevant (10 poäng). 
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SLUTSATSER OCH TILLÄMPNINGSOMRÅDEN 
Förändringar i livskvalitet, eller livskvalitet uppmätt efter operation bland patienter 
med matstrupscancer verkar vara kopplat till överlevnad. En tänkbar förklaring är 
att patienter som har sämre livskvalitet kan ha drabbats av återfall i cancern eller 
har andra sjukdomar som påverkar möjligheten till återhämtning. Denna 
information skulle man kunna använda i det kliniska mötet mellan doktor och 
patient. Redan innan operation kan man ge patienten en realistisk bild av 
återhämtningstiden och den framtida livskvaliteten, och om en patient vid 
uppföljning efter operation uppvisar dåliga värden avseende livskvalitetsmått skulle 
man kunna se det som en öppning för att diskutera eventuella 
behandlingsbegränsningar, samt en eventuellt dålig prognos, med patient och 
anhöriga. Vid en sådan situation måste man dock ta hänsyn till att andra sjukdomar 
förefaller påverka livskvaliteten och doktorer måste sannolikt samverka över 
specialiteterna för att optimera behandlingen av patientens andra sjukdomar i syfte 
att öka livskvaliteten under den kvarvarande tiden i livet.  
Vidare verkar inte kön, ålder och övervikt påverka livskvaliteten efter operation, 
vilket innebär att man som doktor inte bör nöja sig med exempelvis ålder som 
förklaring till en dålig livskvalitet. Istället bör man leta efter andra sjukdomar eller 
cancerfaktorer som förklaring.  
Livskvalitet har av denna avhandling att döma en viktig roll att fylla i det kliniska 
pusslet avseende att få ihop rätt behandling och en realistisk prognos.  
 
 
 
Nyckelord: Livskvalitet, HRQL, esofaguscancer, prognostisk faktor, överlevnad 
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APPENDIX 
 
QLQ-C30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ENGLISH 
 
EORTC QLQ-C30 (version 3)
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
Please fill in your initials: bbbb
Your birthdate (Day, Month, Year): cececdde
Today's date (Day, Month, Year):  31 cececdde
__________________________________________________________________________________________ 
Not at A Quite Very 
  All Little a Bit Much 
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4  
5. Do you need help with eating, dressing, washing  
 yourself or using the toilet? 1 2 3 4 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other 
 leisure time activities? 1 2 3 4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
16. Have you been constipated? 1 2 3 4 
 Please go on to the next page
ENGLISH 
 
During the past week: Not at A Quite Very 
  All Little a Bit Much 
17. Have you had diarrhea? 1 2 3 4 
18. Were you tired? 1 2 3 4 
19. Did pain interfere with your daily activities? 1 2 3 4 
20. Have you had difficulty in concentrating on things, 
 like reading a newspaper or watching television? 1 2 3 4 
21. Did you feel tense? 1 2 3 4 
22. Did you worry? 1 2 3 4 
23. Did you feel irritable? 1 2 3 4 
24. Did you feel depressed? 1 2 3 4 
25. Have you had difficulty remembering things? 1 2 3 4 
26. Has your physical condition or medical treatment 
 interfered with your family life? 1 2 3 4 
27. Has your physical condition or medical treatment 
 interfered with your social activities? 1 2 3 4 
28. Has your physical condition or medical treatment 
 caused you financial difficulties? 1 2 3 4 
For the following questions please circle the number between 1 and 7 that  
best applies to you 
29. How would you rate your overall health during the past week? 
  1 2 3 4 5 6 7 
 Very poor      Excellent 
30. How would you rate your overall quality of life during the past week? 
  1 2 3 4 5 6 7 
 Very poor      Excellent 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
ENGLISH 
EORTC  QLQ – OES18
Patients sometimes report that they have the following symptoms or problems. Please indicate the 
extent to which you have experienced these symptoms or problems  during the past week. Please 
answer by circling the number that best applies to you.   
During the past week: Not A Quite Very 
  at all little a bit much 
31. Could you eat solid food? 1 2 3 4 
32. Could you eat liquidised or soft food?  1 2 3 4 
33. Could you drink liquids?  1 2 3 4 
34. Have you had trouble with swallowing your saliva?  1 2 3 4 
35. Have you choked when swallowing?  1 2 3 4 
36. Have you had trouble enjoying your meals?  1 2 3 4 
37. Have you felt full up too quickly?  1 2 3 4 
38. Have you had trouble with eating?  1 2 3 4 
39. Have you had trouble with eating in front of other people?  1 2 3 4 
40. Have you had a dry mouth?  1 2 3 4 
41. Have you had problems with your sense of taste?  1 2 3 4 
42  Have you had trouble with coughing?  1 2 3 4 
43. Have you had trouble with talking?  1 2 3 4 
44. Have you had acid indigestion or heartburn?  1 2 3 4 
45. Have you had trouble with acid or bile coming into your mouth?  1 2 3 4 
46. Have you had pain when you eat?  1 2 3 4 
47. Have you had pain in your chest?  1 2 3 4 
48. Have you had pain in your stomach?  1 2 3 4 
 QLQ-OES18 Copyright 1999 EORTC Quality of life Group. All rights reserved.  
